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Human and animal studies suggest that females differ in their motivation to use 
methamphetamine (meth), and have increased propensity to relapse.  However, 
addiction pharmacotherapies have primarily only been tested in males, which 
may not accurately predict treatment outcomes in females.  Evidence suggests 
that oxytocin, an endogenous peptide well known for its role in social behaviors 
and childbirth, is a promising addiction pharmacotherapy. This dissertation first 
examines sex differences in the effect of oxytocin to decrease meth and sucrose 
seeking. Our data indicate that systemic oxytocin decreased responding for meth 
differentially in males and females on a progressive ratio schedule of 
reinforcement (a measure of motivation) in females but not males, although it 
reduced reinstatement of meth seeking similarly in both sexes.  To further 
examine these sex differences, we next employed a translational within-session 
behavioral-economic (BE) model designed specifically for meth self-
administration. The BE paradigm allows for measurement of drug demand at 
high effort (motivation; α), normalized based on intake at low effort (baseline 
consumption; Q0) within the same session.  This approach also allowed us to 
assess individual variability in meth demand in relation to relapse behaviors, and 
in response to oxytocin administration.  Our rodent BE paradigm was modeled 
after BE procedures commonly used to assess motivation for reward in humans 




assessed across species, and these variables have been shown to predict later 
relapse behavior.  Therefore, the translational potential of preclinical BE studies 
is particularly strong. We showed that this BE model can predict relapse-like 
behaviors, and that systemic oxytocin acts similarly in both males and females to 
decrease demand (i.e., motivation) for meth and attenuated reinstatement to 
meth seeking. We also demonstrated that oxytocin is most effective at 
decreasing meth seeking in rats with the strongest addiction phenotype. Finally, 
we showed that systemic oxytocin acts via a central mechanism, and more 
specifically through actions in the NAc core. Together these results demonstrate 
that oxytocin modifies multiple meth-seeking behaviors, show the efficacy of 
oxytocin as a pharmacotherapy for addiction in both sexes, and characterize the 
effects of oxytocin on mesolimbic brain circuitry implicated in addiction. Overall, 
these data indicate that oxytocin-based therapies would be a promising treatment 
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CHAPTER 1: Introduction 
 
History of Methamphetamine Abuse 
Methamphetamine (meth), a derivative of amphetamine, was first 
synthesized in 1893 (Suwaki, Fukui et al. 1997). However, the first widespread 
use of the drug did not occur until World War II (WWII), when soldiers in the 
United States, Germany, United Kingdom, and Japan were all documented to 
have used amphetamine or methamphetamine for its stimulant and performance 
enhancing properties (Meredith, Jaffe et al. 2005, Rasmussen 2011). In fact, 
Adolf Hitler was known to use intravenous meth whenever he needed energy, 
and later in his life he exhibited signs of Parkinson’s disease thought to possibly 
be due to his excessive meth use (Doyle 2005). After WWII, Japan suffered from 
the first meth epidemic (Lineberry and Bostwick 2006); however, prescription 
regulations slowed the onset of the epidemic in the United States. Regardless, by 
the 1950’s prevalence of amphetamine abuse was on the rise and prescription 
forms were being promoted for treatment of obesity, narcolepsy, and depression 




amphetamines as a Schedule II drug in 1971 helped to reduce some of the 
abuse problems (Beebe and WALLE 1995, McGuinness 2006).  However, due to 
production by clandestine labs, meth use began rising again in the 1980’s 
(Cunningham and Thielemeir 1996). In response, the United States government 
began to regulate the precursor chemicals used to make meth (Cunningham and 
Liu 2003).  This approach caused the market to transition to acquire meth 
primarily from foreign producers (Cunningham and Liu 2008), namely Mexico, 
and attempting to control this production has been challenging (Shukla, Crump et 
al. 2012).  Overall, meth addiction has been a problem since the early twentieth 
century and remains a significant problem today.  
 
Methamphetamine Addiction    
Meth is a highly addictive psychostimulant that is most commonly smoked 
or snorted, but can also be taken orally or injected (Brecht, O'Brien et al. 2004, 
SAMHSA 2005). However, compared to amphetamine, meth is a much more 
potent stimulant that can more easily cross the blood brain barrier and has a 
longer half-life (~10 h in humans) (Cruickshank and Dyer 2009). Meth addiction is 
a particularly detrimental health problem in the United States and worldwide, with 
over 12 million people (4.7% of the US population) estimated to have tried meth, 
with the number of new users significantly increasing from the previous year 
(SAMHSA 2010).  When occasional abuse of meth transitions into compulsive 
use and addiction, various long-term health consequences result including: 




system, psychotic behavior, increased impulsivity, deficits in memory and 
attention, increased aggression and violence, and alterations in affect and mood 
(Paulus, Hozack et al. 2003, Klasser and Epstein 2005, Hoffman, Moore et al. 
2006, Ikeda, Iwata et al. 2006, McKetin, McLaren et al. 2006, Sekine, Ouchi et al. 
2006, Looby and Earleywine 2007, Salo, Nordahl et al. 2007, Salo, Leamon et al. 
2008, Salo, Nordahl et al. 2008). While the detrimental effects to the addict are 
clear, meth abuse is estimated to cost the United States $23.4 billion a year 
through its effects on crime, unemployment, child abuse or neglect, and other 
social issues (Nicosia, Pacula et al. 2009). 
Meth addiction is a chronically relapsing disorder and addicts who try to 
quit often face severe withdrawal symptoms including craving, disturbed sleep, 
anxiety, depression, and cognitive deficits (Kalechstein, Newton et al. 2003, 
London, Berman et al. 2005, McGregor, Srisurapanont et al. 2005).  While most 
of these symptoms can resolve in days to weeks, cognitive deficits have been 
shown to persist months to years after abstinence (Volkow, Chang et al. 2001, 
Volkow, Chang et al. 2001, Nordahl, Salo et al. 2003, Johanson, Frey et al. 2006, 
Salo, Nordahl et al. 2007). These cognitive deficits early in abstinence can 
compromise executive and psychomotor function, and likely contribute to the 
high rates of relapse (Kalechstein, Newton et al. 2003, Paulus, Tapert et al. 
2005). Thus, despite the great need for effective behavioral and 
pharmacotherapeutic intervention, no satisfactorily effective treatments for meth 





Pharmacology of Methamphetamine 
Similar to other psychostimulants like cocaine, meth produces much of its 
effects by increasing monoamine release. However, as compared to cocaine, 
meth has a significantly longer duration of action and increases monoamine 
release to a much greater degree. Meth has an average half-life of 10 hours (in 
humans), depending on many factors, including the route of administration and 
inter-individual variability (Cruickshank and Dyer 2009). Meth acts as an indirect 
agonist at the dopamine, norepinephrine, and serotonin receptors, and also acts 
as a substitute for these neurotransmitters at their transporters (dopamine (DAT), 
norepinephrine (NET), serotonin (SERT), and the vesicular monoamine 
transporter-2 (VMAT-2) (Sulzer, Sonders et al. 2005). By acting at VMAT-2, meth 
reverses transporter function and causes the monoamines to leave the vesicles 
and enter the cytosol at the synaptic terminal.  In turn, this alters the pH gradient, 
which reverses the endogenous function of DAT, NET, and SERT, releasing the 
neurotransmitters into the synapse (Cruickshank and Dyer 2009). In addition, 
meth inhibits monoamine metabolism by inhibiting monoamine oxidase (Sulzer, 
Sonders et al. 2005). In vitro studies examining these mechanisms have shown 
that meth is twice as effective as releasing norepinephrine than dopamine, and 
60x greater than serotonin (Rothman, Baumann et al. 2001). 
 
Neurotoxicity 
Studies in animals and humans have examined the neurotoxic effects of 




exposure to amphetamines damages dopaminergic and serotonergic neurons, 
potentially via oxidization of these transmitters in the cytosol, which can damage 
nearby proteins and lipids (Cruickshank and Dyer 2009). Additionally, increased 
body temperature is also thought to heavily contribute to these effects (Riddle, 
Hanson et al. 2007). Primate studies show that repeated exposure to meth (in 
doses consistent with human abuse) causes neurotoxicity that can persist for 
more than a year (Villemagne, Yuan et al. 1998, Harvey, Lacan et al. 2000). 
Human PET studies in various brain regions have shown many indicators of 
neurotoxicity including reduced density of DAT (Volkow, Chang et al. 2001, 
Sekine, Minabe et al. 2003) VMAT-2 (Johanson, Frey et al. 2006), SERT (Sekine, 
Ouchi et al. 2006), and D2 receptors (Volkow, Chang et al. 2001). These 
reductions in receptor and transporter density have also been shown to persist 
months to years after cessation of prolonged meth use (Volkow, Chang et al. 
2001, Wang, Volkow et al. 2004, Chang, Alicata et al. 2007). 
 
Animal Models of Addiction 
The most common animal model used to assess relapse-like behaviors is 
the self-administration and reinstatement (relapse) model of addiction, where 
animals respond to receive an i.v. drug infusion accompanied by stimuli that 
become associated with the rewarding effects of the drug via Pavlovian 
conditioning.  Following a period of drug self-administration, subjects undergo 
extinction training.  Reinstatement of drug seeking can then be elicited through 




(primed reinstatement), or stress (e.g., shock-induced reinstatement). This model 
of relapse has face validity largely due to the response contingent drug delivery, 
and the similarity of factors that elicit reinstatement to those that cause drug 
craving and relapse in abstinent individuals (Jaffe, Cascella et al. 1989, Sinha, 
Fuse et al. 2000). However, while animal models of addiction and relapse have 
identified numerous drugs that attenuate drug seeking in animals, most have not 
been effective when tested in humans (Pierce, O’Brien et al. 2012). Thus, in 
Chapters 3 & 4, we will build on the current model and incorporate an economic 
framework in order to mathematically compare animal and human studies and 
potentially increase predictive validity for preclinical testing of potential addiction 
pharmacotherapies.  
Using a behavioral economic framework for valuation of drugs has been 
well characterized across species with the design of many different paradigms 
that allow for a mathematically identical method for quantifying behavior (Hursh 
1980, Hursh and Silberberg 2008). Human studies indicate that behavioral 
economic measures can predict various measures of addiction related behaviors. 
For example, economic demand predicted alcohol dependence, and overall 
lifetime use of heroin, cocaine, and marijuana (Petry 2001, Murphy, MacKillop et 
al. 2009, Gray and MacKillop 2014).  The behavioral economic framework and 







Gender and sex differences in meth addiction 
Meth addiction is a substantial problem that affects both men and women, 
although clinical research has shown numerous sex differences in terms of use 
patterns and responses to treatment (Dluzen and Liu 2008).  Clinical studies 
have shown that females have a greater vulnerability to meth addiction.  
Specifically, females initiate meth use at a younger age (Lin, Ball et al. 2004, 
Hser, Evans et al. 2005), transition faster from recreational use to dependence, 
exhibit greater dependence on meth (Kim and Fendrich 2002, Rawson, Gonzales 
et al. 2005), and have greater comorbidity to other neuropsychiatric disorders 
(Hser, Evans et al. 2005, Yen and Chong 2006). Importantly, these differences 
suggest that females may respond differently to treatment strategies for meth 
addiction.  
Animal models of meth addiction have shown similar sex differences as to 
those seen clinically in human addicts. Compared to males, females acquire self-
administration faster (Roth and Carroll 2004, Kucerova, Vrskova et al. 2009), 
have higher meth intake (Reichel, Chan et al. 2012), and show greater 
reinstatement of meth seeking (Holtz, Lozama et al. 2012, Reichel, Chan et al. 
2012, Cox, Young et al. 2013).  Females also show greater motivation for meth 
on a progressive ratio (PR) schedule of reinforcement (Roth and Carroll 2004, 
Cox, Young et al. 2013). Overall, these studies indicate clear sex differences in 
the motivation to seek meth in humans and animal models; however, almost all 
preclinical studies assessing potential pharmacotherapies for addiction have 





The Nucleus Accumbens and Addiction 
The critical role of the nucleus accumbens (NAc) in mediating the 
addiction process has long been a central focus of addiction research. The NAc 
is a critical interface between the dopaminergic input from the mesocorticolimbic 
projection from the ventral tegmental area and glutamatergic inputs from several 
regions, including the prefrontal cortex and amygdala (Wise 1996, Kalivas and 
O'Brien 2008, Torregrossa, Tang et al. 2008, Carlezon and Thomas 2009). 
Increasing dopamine levels in the NAc is characteristic of all addictive drugs 
(Sacchettini, Frazier et al. 1988, Wise 1996, Phillips, Robinson et al. 2003, 
Phillips, Stuber et al. 2003, Luscher and Ungless 2006, Sulzer 2011) and self-
administration of psychostimulants in particular depends upon effects on 
dopamine signaling in the NAc (Roberts, Koob et al. 1980, Pulvirenti, Maldonado-
Lopez et al. 1992). Further, dopamine and glutamate in the NAc critically mediate 
drug seeking, reinstatement, and other motivated behaviors (Cornish and Kalivas 
2000, Kalivas and Volkow 2005, Kalivas 2009, Floresco 2015). The NAc is 
divided into two major regions: the NAc core (the area surrounding the anterior 
commissure) which has been associated with initiation of motivated behaviors 
(Cornish and Kalivas 2000, McFarland, Lapish et al. 2003) and the NAc shell 
(medial and ventral portions) (Zahm and Brog 1992) which mediates the 
immediate reinforcing actions of psychostimulants (Rodd-Henricks, McKinzie et 
al. 2002, Sellings and Clarke 2003). The NAc contains over 95% GABAergic 




interneurons (Pennartz, Groenewegen et al. 1994, Tepper and Bolam 2004). 
Work in Chapter 4 of this dissertation focuses specifically on the NAc core. The 
next section will elaborate on the NAc, specifically the effects of oxytocin in the 
NAc.  
 
The Oxytocin System 
The endogenous peptide oxytocin is best known for its peripheral actions 
in female parturition and childbirth (e.g., inducing uterine contractions and 
lactation) (Dale 1906, Ott and Scott 1910, Mackenzie 1911). Oxytocin is 
synthesized in magnocellular neurons of the supraoptic and paraventricular 
nuclei (PVN) of the hypothalamus, and secreted via the posterior pituitary for 
peripheral circulation (Renaud and Bourque 1991, Gimpl and Fahrenholz 2001, 
Baskerville and Douglas 2010). Oxytocin is also a centrally active neuropeptide 
that influences many behaviors, including reward-related behavior (Baskerville 
and Douglas 2010). Parvocellular neurons in the PVN send oxytocin efferents to 
multiple brain regions, modulating neuronal activity (Sawchenko and Swanson 
1982, Renaud and Bourque 1991, Baskerville and Douglas 2010, Knobloch, 
Charlet et al. 2012). Oxytocin binds to the Gq class of G protein-coupled 
receptors (GPCRs) activating phopholipase C (PLC) and subsequently 
increasing neuronal firing and neurotransmitter release through this second 
messenger cascade (Strakova and Soloff 1997, Gimpl and Fahrenholz 2001). 
Oxytocin receptors are located throughout the CNS (Gimpl and Fahrenholz 2001) 




bonding, as well as other behaviors such as aggression, stress, and anxiety 
(Milesi-Halle, McMillan et al. 2007, Baskerville and Douglas 2010). 
Oxytocin mediates social and sexual behaviors in part through actions in 
the mesocorticolimbic dopamine system (Baskerville and Douglas 2010). PVN 
oxytocin neurons project to multiple regions of the mesocorticolimbic dopamine 
system (Knobloch, Charlet et al. 2012), including the NAc, ventral tegmental area 






The majority of the studies examining how oxytocin interacts with the dopamine 
system have focused on social behaviors.  For example, oxytocin projections 
from the PVN to the VTA innervate dopamine neurons in the NAc to promote 
sexual behavior (Melis, Melis et al. 2007) and maternal behavior (Shahrokh, 
Zhang et al. 2010), and oxytocin injected into the VTA increases dopamine 
release in NAc (Melis, Melis et al. 2007). Hypothalamic oxytocin cells also 
express dopamine receptors (Baskerville, Allard et al. 2009), suggesting that 
 
 
Figure 1-1 Oxytocinergic projections in the rodent brain. 
The magnocellular neurons of the paraventricular nucleus (PVN, red oval) and 
supraoptic nucleus (SON, blue oval) project to the posterior pituitary to release 
oxytocin peripherally. Parvocellular neurons of the PVN have major projections to 
the nucleus accumbens (NAc), ventral tegmental area (VTA), hippocampus, 
amygdala (AMY), medial preoptic area (MPOA), and olfactory bulb (OB). This 





dopamine may also mediate oxytocin release. In addition, pair bonding in 
monogamous prairie voles is dependent on dopamine interactions in the NAc; 
specifically, D2 receptors promote bonding and D1 receptors inhibit bonding (Liu 
and Wang 2003). The next section will further elaborate on the oxytocin system 
as it pertains to addiction behaviors.  
 
Oxytocin as a Treatment for Addiction 
More recently, oxytocin has been examined as a potential 
pharmacotherapy for addiction (Sarnyai and Kovacs 1994, Baskerville and 
Douglas 2010, Carson, Cornish et al. 2010, McGregor and Bowen 2012, Carson, 
Guastella et al. 2013, Sarnyai and Kovacs 2014). It has been suggested that 
overlap exists between how oxytocin interacts within the mesocorticolimbic 
dopamine system to mediate social behaviors and addiction-like behaviors 
(Burkett and Young 2012), as this system is known to be critical for motivation to 
seek drugs during relapse (Wise 1988, Koob, Sanna et al. 1998, Shaham, 
Shalev et al. 2003, Everitt and Robbins 2005, Kalivas and Volkow 2005, Volkow, 
Fowler et al. 2007, Koob and Le Moal 2008). For example, dopamine in the NAc 
is required for the formation of pair bonds and initial learning of psychostimulant 
self-administration (Burkett and Young 2012). Additionally, D1 agonists block pair 
bond formation and also block some drug seeking behaviors (Burkett and Young 
2012). 
 In clinical studies, oxytocin decreased alcohol withdrawal symptoms and 




individuals (McRae-Clark, Baker et al. 2013). In animal studies, oxytocin has 
been shown to decrease numerous drug-related behaviors for a variety of 
addictive drugs including opiates and alcohol (Kovacs, Sarnyai et al. 1998). For 
the purposes of the dissertation, only those studies that have examined the 
effects of oxytocin on psychostimulants will be discussed.   
Peripheral and centrally-administered oxytocin (intracerebroventricular, 
(ICV)) inhibits cocaine-induced locomotor and stereotyped behavior (Sarnyai and 
Kovacs 1994), as well as meth-induced locomotor activity (Qi, Yang et al. 2008). 
Oxytocin administered systemically and ICV also blocks conditioned place 
preference for meth and reinstatement of the meth-induced preference. (Qi, Yang 
et al. 2009, Baracz, Rourke et al. 2012, Carson, Bosanquet et al. 2012, Subiah, 
Mabandla et al. 2012). In self-administration studies, oxytocin decreased cocaine 
intake during self-administration (Sarnyai and Kovacs 1994, Zhou, Sun et al. 
2014), reinstatement of cocaine-seeking (Morales-Rivera, Hernandez-Burgos et 
al. 2014, Zhou, Sun et al. 2014), and reinstatement of meth-seeking (Carson, 
Cornish et al. 2010, Cox, Young et al. 2013).  
To examine the central site of action for oxytocin on decreasing drug-
reward behaviors, Carson et al. (2010) examined brain regions in which 
systemically-administered oxytocin decreased acute meth-induced neuronal 
activation (Fos activation).  These regions included the NAc core, subthalamic 
nucleus (STN), and prelimbic region of the PFC (Carson, Hunt et al. 2010). 
Further, microinjections of oxytocin in the STN blocked meth-induced CPP and 




2012) and meth-primed reinstatement (Baracz, Rourke et al. 2012). Additionally, 
systemic oxytocin administration blocked cocaine-induced dopamine release in 
the NAc (Kovacs, Sarnyai et al. 1990). In conclusion, oxytocin appears to be 
interacting with the mesocortical dopamine system to attenuate meth seeking; 
however, specific mechanisms have not been determined.  
To date, essentially all preclinical studies examining oxytocin effects on 
drug reward-related behaviors have only used male subjects; thus, it is unclear 
whether these effects extend to females. However, this is an important question 
given that gonadal hormones including testosterone, estrogen, and progesterone 
have been shown to affect oxytocin binding affinity and receptor density in 
various brain regions (Schumacher, Coirini et al. 1990, Coirini, Schumacher et al. 
1991, Patchev, Schlosser et al. 1993). As progesterone and estrogen fluctuate 
during the various estrous cycle phases in female rats, it is important to consider 
how oxytocin may differentially affect females, especially when assessing 
oxytocin as a pharmacotherapy for addiction. Further studies are needed to 
examine whether the effects of oxytocin on drug seeking behaviors differ in 
females. 
The work presented in this dissertation examined the efficacy of oxytocin 
as a pharmacotherapy for meth addiction. First we assessed the effects of 
systemic oxytocin on meth seeking behaviors in males and females. Next we 
developed a within-session behavioral economic model for meth self-
administration to further explore sex differences in the effects of systemic 




systemic oxytocin is attenuating meth seeking behaviors through a peripheral or 
central mechanism. Finally, we examined whether the NAc core is the region 
















CHAPTER 2: Sex Differences in the Effects of 





Oxytocin may have a regulatory role in attenuating drug tolerance, 
dependence, and withdrawal via actions in the mesolimbic dopamine reward 
pathways (Baskerville and Douglas 2010).  Systemic oxytocin blocked cocaine-
induced dopamine release in the nucleus accumbens (Kovacs, Sarnyai et al. 
1990) and decreased cocaine intake during self-administration (Sarnyai and 
Kovacs 1994).  Additionally, recent preclinical evidence suggests that oxytocin 
may have therapeutic benefits in preventing relapse to methamphetamine (meth) 
use (Carson, Cornish et al. 2010).  Of particular note, oxytocin decreased meth 
seeking in an animal model of addiction (Carson, Cornish et al. 2010) and 
reduced meth-conditioned reward (Qi, Yang et al. 2009, Baracz, Rourke et al. 
2012, Subiah, Mabandla et al. 2012) in males.  Oxytocin may be a critical 
regulator in drug addiction via modulation of dopaminergic transmission in 




2010).  For example, oxytocin decreased dopamine release and receptor binding 
in mesolimbic brain structures (Sarnyai and Kovacs 1994).  Support for the use 
of oxytocin as an addiction treatment has gained momentum, due in part to the 
prosocial effects associated with some drugs of abuse (Dumont, Sweep et al. 
2009).  Further, neural circuits mediating social bonding and drug reward may 
overlap (Burkett and Young 2012).    
To date, the ability of oxytocin to ameliorate meth seeking or conditioned 
reward in female rats is unknown.  However, this is an important question given 
that gonadal hormones regulate oxytocin’s binding affinity and receptor density in 
various brain regions (Schumacher, Coirini et al. 1990, Coirini, Schumacher et al. 
1991, Patchev, Schlosser et al. 1993).  Further, progesterone and estrogen 
fluctuate throughout the estrous cycle in female rats, rendering studies with 
females a necessity to determine oxytocin’s full potential as a 
pharmacotherapeutic treatment for meth addiction.  Clinical research in meth 
addiction indicates numerous sex differences in terms of meth use patterns and 
response to treatment (reviewed in (Dluzen and Liu 2008).  For example, women 
tend to initiate meth use at a younger age (Dluzen and Liu 2008), transition faster 
to dependence, exhibit greater dependence (Kim and Fendrich 2002, Rawson, 
Gonzales et al. 2005), and have greater comorbidity with other neuropsychiatric 
disorders (Hser, Evans et al. 2005, Yen and Chong 2006).  While clinical 
evidence has shown gender differences, preclinical research investigating meth 
addiction and potential pharmacotheraputic treatments has primarily focused only 




differentially to treatments when compared to males, suggesting a need for 
gender/sex specific therapies.  Consistent with clinical populations, animal 
models indicate that female rodents have an increased sensitivity to meth’s 
psychomotor stimulating effects (Schindler, Bross et al. 2002, Milesi-Halle, 
McMillan et al. 2007).  
Animal models of drug self-administration incorporate various aspects of 
the addiction cycle, including motivation to consume a drug and/or drug seeking 
behavior in the absence of reinforcement.  Self-administration models require 
animals to learn to press an operandum (typically a lever) for an intravenous drug 
infusion.  In these models, more female rats acquire meth self-administration 
relative to males (Roth and Carroll 2004), exhibit higher meth intake (Reichel, 
Chan et al. 2012), and exert more effort for meth as a primary reward (Roth and 
Carroll 2004).  Meth seeking can be inferred by the reinstatement of lever 
responding following a period of non-reinforced responding.  These 
reinstatement tests incorporate various trigger factors (e.g., cues, drug-priming, 
or stress) for the testing of pharmacotherapies that may block reinstatement 
(Yahyavi-Firouz-Abadi and See 2009).  
Here, we assessed whether systemic oxytocin may be a potential 
treatment for meth addiction in females and males.  To this end, we first 
determined the effects of oxytocin on meth-primed reinstatement of meth seeking 
throughout the various stages of the estrous cycle in female rats.  Second, we 
determined whether oxytocin would impact motivation for meth in both males and 




meth priming, or pharmacological stress (yohimbine) induced reinstatement.  
Finally, we determined whether oxytocin effects would extend to natural 







 A total of 22 male and 39 female Long-Evans rats (Charles River, Raleigh, 
NC) weighing 250-300 g and 180-200 g, respectively, at the time of arrival, were 
used. All rats were individually housed on a reversed 12:12 light-dark cycle in a 
temperature and humidity controlled vivarium.  Water was available ad libitum 
throughout the study and rat chow (Harlan, Indianapolis, IN, USA) was provided 
daily until SA stabilized, after which time food was provided ad libitum.  All 
experimental procedures were approved by the Institutional Animal Care and 
Use Committee of the Medical University of South Carolina and were in 
accordance with the “Guide for the Care and Use of Laboratory Rats” of the 
Institute of Laboratory Animal Resources on Life Sciences, National Research 
Council.  
 
Surgery and drugs 
 Rats were anesthetized with IP injections of ketamine (66 mg/kg; Vedco 
Inc, St. Joseph, MO, USA), xylazine (1.3 mg/kg; Lloyd Laboratories, Shenandoah, 
IA, USA), and Equithesin (0.5 ml/kg; sodium pentobarbital 4 mg/kg, chloral 
hydrate 17 mg/kg, 21.3 mg/kg magnesium sulfate heptahydrate dissolved in 44% 
propylene glycol, 10% ethanol solution).  Ketorolac (2.0 mg/kg, IP; Sigma 
Chemical, St. Louis, MO) was given before surgery as an analgesic.  Catheters 




inserted 33 mm into the right jugular vein and secured with silk sutures. During 
recovery from surgery, catheters were flushed once daily for 5 days with 0.1 ml of 
Timentin (24 mg/0.1; GlaxoSmithKline, Research Triangle Park, NC) and 10 U/ml 
of heparinized saline (Elkins-Sinn, Cherry Hill, NJ).  During meth self-
administration (methamphetamine hydrochloride; Sigma Chemical, St. Louis, 
MO), catheters were flushed with 0.1 ml of 10 U/ml heparinized saline before and 
after every self-administration session.  Catheter patency was periodically 
verified with methohexital sodium (10 mg/ml dissolved in 0.9% saline; Sigma 
Chemical, St. Louis, MO), a short acting barbiturate that produces a rapid loss in 
muscle tone when administered intravenously.  Oxytocin (1 mg/ml dissolved in 
ddH20; Cell Sciences, Canton, MA) was administered prior to PR and 
reinstatement testing, and yohimbine hydrochloride (2.5 mg/ml dissolved in 
ddH20; Sigma Chemical, St. Louis, MO) was used for stress-induced 
reinstatement (Shepard, Bossert et al. 2004, See and Waters 2010). 
 
Self-administration 
 Self-administration procedures were based on recent studies of meth self-
administration in males (Reichel and See 2010, Reichel, Chan et al. 2012, 
Mahler, Moorman et al. 2013).  All self-administration experiments were 
conducted during the rats’ dark cycle in standard Plexiglas self-administration 
chambers (30 X 20 X 20 cm) that were enclosed in sound attenuating cubicles 
with a ventilation fan (Med Associates, St. Albans, Vermont) and linked to a 




chamber was equipped with two retractable levers with a white stimulus light 
above each lever, house light, and tone generator.  For meth self-administration, 
infusion tubing enclosed in steel spring leashes (Plastics One Inc., Roanoke, VA) 
was connected to the infusion harness and a weighted swivel apparatus (Instech, 
Plymouth Meeting, PA) was suspended above the box to allow for free 
movement within the chamber.    
Self-administration sessions were conducted 6 days/week to criterion (14 
sessions > 10 infusions).  The house light remained on throughout the sessions 
and a response on the active lever resulted in activation of the pump and delivery 
of a 2-sec meth infusion (17.5 µg/50 µl bolus for females and 20 µg/50 µl bolus 
for males) and a 5-sec presentation of a stimulus complex (illumination of the 
white stimulus light over the active lever and activation of tone generator; 78 dB, 
4.5 kHz), followed by a 20-sec time-out.  During the time-out period, responses 
on the active and inactive levers were recorded, but had no scheduled 
consequences.   
 
Progressive ratio schedule of reinforcement 
PR tests were conducted when stable self-administration was evident 
based on the criteria of 14 days with more than 10 reinforcers earned.  Before 
tests, rats were injected with oxytocin (1 mg/kg) or vehicle.  Test order was 
counterbalanced, and between tests, rats received a minimum of 2 self-
administration sessions.  During these tests, reinforcement was contingent upon 




following progression: 1, 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, 50, 62, 77, 95, 118, 
145, 178, 219, 268, 328, 402, 492, 603 (Richardson and Roberts 1996).  The 
session terminated if a rat failed to receive an infusion or sucrose pellet for 1 h or 
after a total of 5 h. 
 
Extinction and reinstatement 
Following self-administration, rats underwent 2 h daily extinction sessions 
for a minimum of 10 days, where responses on both the active and inactive 
levers were recorded, but had no scheduled consequences.  Extinction criterion 
consisted of <25% responding on the active lever relative to the last 5 days of 
self-administration.  Upon reaching criteria, rats underwent cue-, meth-, and 
yohimbine-induced reinstatement testing.  Prior to all reinstatement tests, rats 
received either an injection of oxytocin (0.3 or 1 mg/kg) or vehicle (IP) 30 min 
before testing (see specific experimental methods detailed below).  For cue-
induced reinstatement, responding on the active lever resulted in presentation of 
the light+tone stimulus complex along an FR5 schedule of reinforcement.  For 
drug-primed reinstatement tests an injection of meth (1 mg/kg dissolved in 0.9% 
physiological saline, IP) was given immediately prior to testing (Schwendt, Rocha 
et al. 2009, Reichel, Chan et al. 2012).  Prior to stress-induced reinstatement 
tests, an injection of yohimbine hydrochloride (2.5 mg/kg, IP) was given after 
oxytocin or vehicle, 30 min prior to testing.  During both meth-primed and 
yohimbine-induced reinstatement tests, responses on either lever were recorded, 




tests, rats experienced a minimum of 2 extinction sessions, or until extinction 
criterion was met. 
 
Estrous cycle monitoring  
Female rats were habituated to vaginal cytology procedures during self-
administration.  Vaginal lumen samples were collected by gently flushing 30 µl of 
ddH20 with a sterile saline-dipped pipette tip and extracting the sample using a 
micropipette before rats were placed in the self-administration chambers.  
Collected samples were smeared on to a glass slide, stained with Quik-Dip 
Hematology Stain (Mercedes Medical, FL), and examined for classification of 
cycle phase (estrus, proestrus, and diestrus I/II) based on previously published 
criteria (Marcondes, Bianchi et al. 2002, Feltenstein, Henderson et al. 2011) with 
a light microscope set at 10x magnification.  
 
Experiment 1: Oxytocin effects on meth-primed reinstatement across the 
estrous cycle 
Female rats (n=10) self-administered meth along a FR 1 schedule of 
reinforcement throughout the self-administration phase. Following self-
administration and extinction, rats underwent nine meth-primed reinstatement 
tests with pretreatment of 0, 0.3, and 1 mg/kg oxytocin.  When possible, rats 
were tested during each of the phases of their estrous cycle (estrus, proestrus, 




minimum of 2 extinction sessions occurring between tests, or until subjects 
returned to criterion.  
 
Experiment 2:  Oxytocin effects on meth self-administration and 
reinstatement 
Male (n=15) and female (n=17) rats initially self-administered meth along a 
FR1 schedule of reinforcement until they reached criterion of a minimum of 5 
days with >10 infusions (with <25% change in the number of infusions for 2 
consecutive days).  Rats then moved to a FR3 schedule for a minimum of 3 days, 
followed by a FR5 schedule for the remainder of the self-administration sessions.  
Testing on the PR reinforcement schedule followed stable responding on the 
FR5.  Following these tests, extinction criterion was met and all rats underwent 3 
types of reinstatement tests in the following order: cue-induced, meth-primed, 
and yohimbine-induced, each counterbalanced for oxytocin (1 mg/kg) or vehicle 
pretreatment for a total of 6 reinstatement tests.  Test order did not interact with 
reinstatement responding.  
 
Experiment 3:  Oxytocin effects on sucrose self-administration and 
reinstatement  
 Males (n=7) and females (n=12) underwent identical procedures as rats in 
Experiment 2, with the following exceptions.  Instead of meth, sucrose pellets (45 
mg, Noyes pellets, Fisher Scientific) served as the primary reinforcer.  Sucrose 




tests, rats received one non-contingent pellet every 2 min for the first 10 min of 
the session and one pellet every 30 min thereafter, modified from previous 
procedures (Kumaresan, Yuan et al. 2009).  
 
Data analysis 
The number of lever responses, breakpoint, and infusions were the 
primary dependent variables and were analyzed using analysis of variance 
(ANOVA).  For reinstatement testing, lever responses were analyzed using a 
two-way ANOVA with sex and oxytocin pretreatment as between subject factors.  
Post hoc analyses were conducted using Bonferroni’s when applicable, with the 
alpha set at 0.05.  All data are expressed as the mean ± SEM.  
 
Results  
Experiment 1: Estrous cycle effects on meth-primed reinstatement with 
oxytocin pretreatment 
 Figure 2-1 depicts meth-primed reinstatement at three doses of oxytocin 
(0, 0.3, and 1 mg/kg) during the three phases of the estrous cycle (proestrus, 
diestrus I/II, estrus).  Overall, oxytocin dose did not interact with estrous cycle, 
nor was there a main effect of estrous cycle.  However, there was a main effect 
of oxytocin dose [Figure 2b, F(2,66)=4.63, p<0.05].  Specifically, 1 mg/kg 





Figure 2-1 Meth-primed reinstatement to meth seeking in females following 
oxytocin pretreatment.   
A) Active lever responding during reinstatement by estrous cycle phase and dose 
of oxytocin.  No effect of cycle phase was seen during meth-primed 
reinstatement with or without oxytocin.  B) Active lever responding during 
reinstatement by dose of oxytocin.  Oxytocin (1 mg/kg) significantly decreased 
active lever responding as compared to vehicle (*p<0.05). 
 
Experiment 2: Oxytocin effects on meth self-administration and 
reinstatement 
 Figure 2-2 depicts the impact of oxytocin on PR performance (lever 
presses, break points, and infusions) for males and females during meth self-
administration.  Overall, females had more active [Figure 2A, sex main effect, 
F(1,28)=6.26, p<0.05] and inactive (Table 1, sex main effect, F(7,28)=4.48, 
p<0.05] lever responses as compared to males.  Oxytocin decreased active lever 
responding [treatment main effect, F(1,28)=10.8, p<0.001], an effect that was 
driven primarily by females [p<0.05].  Consistently, females had a higher 
breakpoint than males [Figure 2B, sex main effect, F(1,28)=5.68, p<0.05].  
Oxytocin decreased breakpoints [treatment main effect, F(1,28)=10.31, p<0.001] 




infusions (Figure 2-2C), and oxytocin pretreatment decreased infusions earned 
[treatment main effect, F(1,28)=14.08, p<0.001] more in females than in males 
[p<0.05].   
 
Figure 2-2.  Progressive ratio (PR) responding in males and females during 
meth self-administration.   
A) Active lever responding in males and females after oxytocin or vehicle.  




Oxytocin decreased active lever responding for females, but not males.  B) 
Breakpoint during PR tests. Females had a higher breakpoint relative to males 
and oxytocin (1 mg/kg) reduced the breakpoint in females, but not males.  C) 
Number of infusions during PR tests.  Oxytocin decreased the number of 
infusions for females, but not males.  Significant differences from same sex 
control (*p<0.05) or between males and females treated with vehicle  (†p<0.05) 
are indicated. 
 
 Figure 2-3 depicts self-administration, extinction, and reinstatement data 
for meth self-administration in males and females.  Figure 2-3A shows the 
average active lever responding over the last 5 days of self-administration and 
the last 2 days of extinction.  No differences emerged between males and 
females in active or inactive lever presses (see Table 1 for inactive lever data).  
However, females (14.50±1.19) took more days to meet extinction criterion than 
males (10.93±0.62).   
 
 
 After extinction, the rats were first tested on cue-induced reinstatement 
tests (Figure 2-3B).  Active lever presses for males and females varied according 
to treatment.  Overall, females responded more during cue-induced 
reinstatement than males and oxytocin attenuated active lever responding only in 
females [sex x treatment interaction, F(1,24)=7.35, p<0.05, and post hoc, p<0.05].  
Oxytocin also decreased inactive lever responding [Table 1, treatment main 
effect, F(1,24)=1.56, p<0.05].  During meth-primed reinstatement (Figure 2-3C) 
females had more active lever responses [sex main effect, F(1,24)=4.52, p<0.05] 
and oxytocin decreased active [treatment main effect, [F(1,24)=51.14, p<0.0001] 




responding in both females and males.  Rats were then tested on a yohimbine 
stress induced reinstatement test (Figure 2-3D).  During yohimbine-induced 
reinstatement, females reinstated to a greater extent than males [sex main effect, 
F(1,20)=5.73, p<0.05] and oxytocin attenuated active [treatment main effect, 
F(1,20)=16.87, p<0.001] and inactive [Table 1, treatment main effect, 
[F(1,22)=4.35, p<0.05] lever responding in both sexes.  
Table 1 Mean inactive lever responding during sucrose self-administration, 








Figure 2-3 Active lever responding during meth self-administration and 
subsequent reinstatement tests.   
A) Active lever responding during that last 5 days of self-administration and the 
last 2 days of extinction in males and females.  B) Active lever responding during 
cue-induced reinstatement in males and females after oxytocin or vehicle.  
Females reinstated to conditioned cues to a greater extent than males.  Oxytocin 
decreased cue-induced reinstatement in females, but not males.  C) Active lever 
responding during meth-primed reinstatement.  Females responded more during 
the meth prime test than males.  Oxytocin decreased meth-primed reinstatement 
in both males and females.  D) Active lever responding during stress-induced 
reinstatement by yohimbine.  Oxytocin decreased yohimbine-induced 
reinstatement in males and females.  Significant differences from same sex 









Experiment 3:  Oxytocin effects on sucrose self-administration and 
reinstatement  
 Figure 4 depicts the impact of oxytocin on lever presses, infusions, and 
break points during the PR tests for sucrose self-administration in females and 
males.  There were no sex differences or oxytocin effects on the number of 
active (Figure 2-4A) or inactive (Table 2) lever presses, break point (Figure 4B), 
or pellets earned (Figure 2-4C).  
 
 
Figure 2-4 Progressive ratio (PR) responding for males and females during 
sucrose self-administration.   
There were no differences in A) active lever responding, B) breakpoints, or C) 
pellets earned during PR tests in males and females after oxytocin or vehicle.   
 
 Figure 2-5A shows the average active lever responding over the last 5 




stabilized), and no differences were seen between males and females.  
Extinction responding did not differ during the last 2 days between sexes.  
Following extinction, the rats were first tested on a cue-induced reinstatement 
test (Figure 2-5B).  Females responded more on the active lever than males [sex 
main effect, F(1,13)=6.97 p<0.05].  Oxytocin did not affect responding in either 
sex.  On the sucrose prime test (Figure 2-5C), oxytocin decreased active lever 
responding in both females and males [treatment main effect, [F(1,13)=8.61, 
p<0.05].  In addition, during the yohimbine-induced reinstatement test, oxytocin 
attenuated active lever responding in both sexes [Figure 2-5D, F(1,13)=8.01, 
p<0.005].  Responding on the inactive lever did not differ on any measure for 
sucrose-trained rats (Table 2.) 
Table 2 Mean inactive lever responding during sucrose self-administration, 







Figure 2-5 Active lever responding during sucrose self-administration and 
subsequent reinstatement tests in males and females treated with oxytocin 
or vehicle.   
A) Active lever responding during that last 5 days of self-administration and the 
last 2 days of extinction in males and females.  B) Active lever responding during 
cue-induced reinstatement in males and females after oxytocin or vehicle.  
Females reinstated to conditioned cues to a greater extent than males.  Oxytocin 
decreased cue-induced reinstatement in females, but not males.  C) Active lever 
responding during sucrose-primed reinstatement.  Females responded more 
during the sucrose prime test than males.  Oxytocin decreased sucrose-primed 
reinstatement in both males and females.  D) Active lever responding during 
stress-induced reinstatement by yohimbine.  Oxytocin decreased yohimbine-
induced reinstatement in males and females.  Significant differences from same 
sex control (*p<0.05) or between males and females treated with vehicle  
(†p<0.05) are indicated. 
 
Discussion  
 Here, we have established that the ability of systemic oxytocin to reduce 




Also, we found sex specific effects of oxytocin in reducing motivation to take 
meth, as well as reward seeking in response to conditioned reinforcers.  The 
similarities between sexes were evident by the ability of oxytocin to decrease 
meth seeking in both males and females in response to a drug prime and a 
pharmacological stressor.  To date, only one study exists (Holtz, Lozama et al. 
2012) that directly compared the ability of a treatment compound 
(allopregnanolone or modafinil) to block reinstatement to meth seeking in both 
males and females.  However, prior studies with rats have clearly demonstrated 
pronounced differences between male and female meth intake (Reichel, Chan et 
al. 2012), motivation to self-administer meth (current report, (Roth and Carroll 
2004), and reinstatement of meth seeking (Holtz, Lozama et al. 2012, Reichel, 
Chan et al. 2012).  
 In the first experiment, estrous cycle did not interact with oxytocin during 
meth-primed reinstatement testing and females reinstated to a meth prime 
regardless of cycle phase.  As such, neither meth-primed reinstatement nor 
attenuation with oxytocin appeared to be influenced by circulating ovarian 
hormones.  However, PR responding and reinstatement tests were conducted 
based on response criteria, rather than estrous cycle for the females.  Therefore, 
the possibility remains that the reported sex differences may be due, in part, to 
differential regulation of oxytocin receptor affinity, surface expression, and/or 
coupling mechanisms by estrogen and progesterone.  For example, estrogen 
increased oxytocin receptor affinity in the medial preoptic area of the 




ventromedial nucleus (Coirini, Schumacher et al. 1991).  Additionally, 
progesterone increased oxytocin receptor density in limbic structures (Patchev, 
Schlosser et al. 1993), which could subsequently increase the effects of oxytocin 
in females relative to males.  Fluctuations in gonadal hormones may account for 
the sex differences in motivation to take meth during the PR tests and meth 
seeking during cue-induced reinstatement.   
 Oxytocin reduced responding for meth along the PR schedule of 
reinforcement in females down to a level comparable to males.  However, 
motivation for sucrose was similar in males and females regardless of 
pretreatment condition.  In males, oxytocin did not have an effect on either meth 
or sucrose taking during the PR.  A distinction between drug and natural reward 
occurred in females, as oxytocin only decreased meth taking, but not sucrose 
taking, during the PR.  Interestingly, females in general demonstrated greater 
motivated meth taking, which is in line with previous self-administration studies 
with meth (Roth and Carroll 2004), cocaine (Roberts, Bennett et al. 1989, Carroll, 
Morgan et al. 2002), and heroin (Cicero, Davis et al. 2002).  While we found the 
ability of oxytocin to reduce motivation to obtain meth was specific to females, a 
previous study showed that oxytocin (1 mg/kg) decreased responding on a 
similar PR tasks in male rats (Carson, Cornish et al. 2010).  These contrasting 
findings in males likely arise from several methodological differences between 
studies.  For example, in our study, rats were maintained on a FR schedule of 
reinforcement and two PR ratio tests were given in a counterbalanced manner 




earlier study transitioned to and maintained their responding along a PR 
schedule of reinforcement and oxytocin administration occurred on five 
consecutive days with ascending doses.  As such, these repeated daily doses of 
oxytocin might have resulted in a sensitized response to oxytocin.  Also, rats 
maintained along a PR schedule received fewer daily meth infusions on average 
than rats in our study that were maintained along a FR.  The increased meth 
intake for males may have rendered them less susceptible to lower doses of 
oxytocin (i.e., oxytocin’s efficacy may be related to total meth intake). 
 Oxytocin only reduced cue-induced reinstatement in meth females, 
indicating some specificity for sex and conditioning of drug-cue associations.  For 
example, in females, oxytocin decreased responding for meth-conditioned cues, 
but not sucrose.  This difference indicates that oxytocin has some degree of 
specificity to reduce relapse to drug related cues, rather than those associated 
with natural reward.  Alternatively, different response rates between the meth and 
sucrose studies provide a potential explanation for this difference.  Specifically, 
the sucrose females received on average 561.8 (±25.4) primary and secondary 
reinforcers (i.e., sucrose pellets and light + tone stimulus complex) during the last 
5 days of self-administration as compared to the meth females that received 
162.9 (±10.5) reinforcers.  Consequently, this difference in response rate and 
reinforcement history may have rendered sucrose females less susceptible to 
oxytocin’s ability to attenuate cue-induced reward seeking.  
 In the current study, females responded more to meth and sucrose 




females responded equally to males in response to conditioned cues during 
reinstatement of cocaine (Feltenstein, Henderson et al. 2011, Zhou, Ghee et al. 
2012) or nicotine (Feltenstein, Ghee et al. 2012) seeking.  Importantly, these 
effects were evident when rats were trained and tested along an FR1 schedule of 
reinforcement.  Meth rats in our study were trained and tested on an FR5 
schedule of reinforcement, whereby the light + tone stimulus complex occurred 
after every 5 active lever presses during the reinstatement test.  Male meth rats 
had low levels of reinstatement on this test schedule relative to our experiences 
typically observed with FR1 cue-induced reinstatement (Reichel and See 2010, 
Reichel, Chan et al. 2012), suggesting a possible floor effect. In spite of the low 
reinstatement in males, females demonstrated markedly more robust 
reinstatement in the identical situation.  Surprisingly, females were impervious to 
the lean reinforcement schedule during cue-induced reinstatement.  This 
enhanced responding to conditioned reinforcers suggests that females may 
entrain the original associations to a greater degree than males, indicating 
differences in interpretation of the associative strength of the reward.  Associative 
strength is defined as the degree of strength of learning that occurs between a 
conditioned stimulus (CS, i.e., light + tone) and the unconditioned stimulus (US, 
i.e., physiological effects of meth or sucrose).  Increased meth-cue and sucrose-
cue reinstatement in females may be due to increased salience or value of the 
US, which imbues the associative strength of the CS.  Support for this notion 
comes from a demonstration that estrogen enhanced conditioned learning in 




utilized freely cycling females with an intact hormonal system, fluctuations in 
estrogen and progesterone levels during self-administration may have influenced 
the original associative processes.   
  Oxytocin was equally effective at reducing reinforcer-primed 
reinstatement of meth and sucrose seeking, although females reinstated to a 
greater extent to a meth prime than males.  This sex difference has been seen 
before and demonstrates that, regardless of session length, females exhibit 
enhanced meth seeking to a priming injection [current report, (Holtz, Lozama et 
al. 2012, Reichel, Chan et al. 2012)].  Importantly, meth-primed reinstatement did 
not depend upon estrous cycle phase for females, nor did cycle interact with the 
ability of oxytocin to reduce meth seeking.  In fact, oxytocin reduced prime-
induced meth seeking during all cycle phases for females.  Further, oxytocin 
decreased sucrose seeking during sucrose primed reinstatement tests.  Taken 
together, oxytocin decreased seeking for both meth and sucrose during the 
reinstatement tests in both sexes.  This effect suggests that oxytocin decreased 
seeking for both drug and natural reward, perhaps through similar mechanisms.  
Although the underlying mechanisms are beyond the scope of this study, one 
suggestion relies on the interaction of oxytocin with the dopamine system 
(Baskerville and Douglas 2010).  Oxytocin may decrease the saliency of reward 
via interactions with dopamine activity in regions known to be involved in drug 
seeking.  For example, oxytocin attenuated meth-induced dopamine efflux in the 
nucleus accumbens (Qi, Yang et al. 2009), decreased meth-induced Fos 




regulated meth-induced changes in extracellular glutamate and γ-aminobutyric 
acid (GABA) in mouse brain (Qi, Han et al. 2012).  Future studies will need to 
directly elucidate the mechanism by which oxytocin attenuates drug seeking. 
 In all subjects, oxytocin attenuated yohimbine-induced reinstatement, 
suggesting a common mechanism for reductions in stress-induced reinstatement. 
Oxytocin produces anxiolytic effects in humans (Macdonald and Macdonald 
2010) and animals (Neumann, Wigger et al. 2000) through inhibition of the 
hypothalamic-pituitary-adrenal axis, which is a sex independent effect in rats 
(Neumann, Wigger et al. 2000).  The pharmacological stressor, yohimbine, 
produced similar reinstatement in both sexes of rats with a meth history.  This 
finding was somewhat surprising, given that female cocaine addicts are 
purportedly more likely to relapse to stressful life events (McKay, Rutherford et al. 
1996, Back, Brady et al. 2005).  However, results have been somewhat mixed in 
animal models of relapse with cocaine.  While one study showed greater 
yohimbine-induced reinstatement in females relative to males (Anker and Carroll 
2010), our laboratory previously reported that sex differences in reinstatement 
only emerged when cues were simultaneously presented in combination with 
yohimbine (Feltenstein, Henderson et al. 2011).  In the current study, we also 
found no sex differences in yohimbine-induced reinstatement of sucrose seeking.  
Earlier reports showed that yohimbine reinstated sucrose seeking in males 
(Ghitza, Gray et al. 2006, Richards, Simms et al. 2008), but to our knowledge, 




 Although inactive lever presses were uniformly lower than active lever 
presses, oxytocin reduced inactive lever presses in rats with a history of meth 
self-administration, but not sucrose.  Changes in inactive lever responding could 
indicate alternative strategies in exploratory drive for reward and/or non-specific 
motor behavior.  These options are unlikely, however, as pilot data from our 
laboratory has found that oxytocin (1 mg/kg) does not reduce meth-induced or 
basal motor activity beyond baseline values (data not shown).  Furthermore, 
oxytocin did not decrease responding for sucrose during the PR test, suggesting 
an effect specific to meth-experienced rats.  
 In conclusion, we report: 1) oxytocin reduced motivation to self-administer 
meth in females, but not males; 2) females responded more to conditioned 
reinforcers during cue-induced reinstatement tests; and 3) sex similarities in the 
ability of oxytocin to decrease meth and sucrose seeking in response to either a 
meth prime or a pharmacological stressor.  Oxytocin appears to have the 
greatest influence on meth-experienced females, decreasing motivation and 
relapse in response to cue, meth prime, and yohimbine-induced reinstatement.  
In contrast, oxytocin only impacted males in response to meth and yohimbine-
primed reinstatement.  Taken together, these results indicate that oxytocin or 
oxytocin receptor agonists may be a promising pharmacotherapeutic treatment 
strategy for meth addiction in both males and females in response to multiple 
relapse triggers.  
 These data indicate that oxytocin differentially affects meth seeking in 




cue-induced reinstatement. Further studies are needed to more specifically 









Chapter 3: Behavioral Economics of Drug Addiction 
 
 
Behavioral economics (BE) has been termed “a science of behavior” 
(Hursh 1984) and a general term used to describe any concept or method of 
applying economic theory to analyze behavior of individuals (Bickel, Green et al. 
1995). This theory came about in the 1950’s-1960’s, although many argue that 
these concepts existed before then (Hosseini 2003). Over the years behavioral 
economics has become a broad term used to describe many different methods 
and theories. For the purposes of this dissertation, one crucial aspect of BE is 
consumer demand theory, which describes how demand for rewards varies by 
the price a subject is willing to pay to receive the reward (Hursh, Raslear et al. 
1988). Evidence suggests that consumption of addictive drugs, like other goods, 
can be examined in terms of this economic concept. For example, to assess a 
demand curve, subjects are asked how much drug they would purchase at 
multiple prices. These data can then be plotted, and typically a negative slope is 
produced following the law of demand (i.e., demand decreases as the prices 




addicts often end up paying not only financial, but also career and relationship 
costs.  
BE paradigms are particularly useful as a measure of drug demand since 
they allow for parallel quantitative analyses of this addiction-related demand 
across species (including humans, non-human primates, and rodents)(Fig 3-1).  
 
Figure 3-1 Example demand curves for rats and humans. 
A) Mean meth demand curve for males (blue) and females (pink) during our BE 
paradigm for number of meth infusions (consumption) by increasing FR value 
(cost).  B) Mean alcohol demand curve of college students by alcohol 
consumption with increasing price of drinks. Graph B was adapted from (Murphy, 
MacKillop et al. 2009). 
 
The BE paradigm measures consumption of drug during both low-effort and high-
effort (i.e., low-price and high-price) conditions, providing a quantitative analysis 
of motivation for meth normalized for differences in baseline intake.  These 
assessments are derived from economic equations that describe drug demand 
(consumption) as a function of drug price (effort required to obtain drug) (Hursh 




and Pmax, (Hursh and Silberberg 2008). Importantly, the same variables can be 
assessed across species, allowing direct comparison of rewards and 
manipulations.  Q0, Omax, and Pmax can be estimated graphically from response 
curves, while α must be calculated using the exponential demand equation 
(Equation 1) (Hursh and Silberberg 2008). 
 
In Equation 1, Q is the measure of consumption (i.e., demand), Q0 is the 
measure of demand when price or cost (C) approaches 0, k specifies the range 
of Q, and α is a measure of demand curve elasticity (i.e., how quickly demand 
falls with increases in price) (Hursh and Silberberg 2008). 
As it is known that increased effort will decrease consumption, 
assessment of Q0 is a calculated variable which predicts demand for 
consumption at null effort and is extrapolated from consumption during low effort 
(i.e., cost) conditions (Hursh and Silberberg 2008). To further expand on the 
definitions above in terms of drug taking behaviors, in humans Q0 would be the 
amount of drug they would choose to take if there were an unlimited amount, or 
for rodents in a self-administration paradigm, how much drug they would choose 
to consume in the absence of required effort (e.g., lever presses). In humans, Q0 
has been shown to significantly correlate with several measures of addiction (e.g., 
motivation to quit smoking, problem drinking) for both alcohol and nicotine 
(MacKillop and Murphy 2007, Murphy, MacKillop et al. 2009, MacKillop, Miranda 
et al. 2010, MacKillop, O'Hagen et al. 2010, Murphy, MacKillop et al. 2011) 





Additionally, α is a measure of demand curve elasticity, meaning the 
estimated price an individual is willing to pay for a drug. For example, in humans 
this can be assessed based on how much money an individual will pay for a drug, 
or for rodents how much effort (i.e., lever presses) they are willing to put forth to 
receive the drug. α is calculated based on Equation 1, which normalizes α in 
respect to Q0 (Hursh and Winger 1995, Spiga, Martinetti et al. 2005, Hursh and 
Silberberg 2008, Bentzley, Fender et al. 2013), allowing for direct comparison 
across reinforcers (Ko, Terner et al. 2002, Winger, Hursh et al. 2002, Winger, 
Galuska et al. 2006, Wade-Galuska, Winger et al. 2007). This normalized 
measure of demand is shown to be superior to the measurement of Pmax (the 
maximum price the individual is willing to pay) in studies of addiction-like 
behavior. For example, α but not Pmax predicted the number of alcoholic drinks 
consumed per week, problems that occurred because of alcohol, and the amount 
college students spent on alcohol (Murphy, MacKillop et al. 2009). Additionally, α 
but not Pmax predicated subsequent addiction-related behavior, including the 
number of cigarettes adolescent smokers smoked per day (Murphy, MacKillop et 
al. 2011). Therefore, this dissertation concentrated on the assessment of Q0 and 
α for all BE studies. Figure 3-2 depicts where Q0 and α are assessed on an 






Figure 3-2 Representation of where Q0 and α are assessed on a demand 
curve. α is a measure of demand curve elasticity and is a calculated variable 
(normalized to Q0) that represents the point at which the demand for the drug 
begins to decrease. Q0 is an estimate of drug consumption at the price of zero 
and is calculated by extrapolating consumption during low effort (i.e., FR1) 
conditions. 
 
Demand curve analysis is a particularly useful method of characterizing 
drug self-administration, because it can measure intake at low cost (desired 
intake levels; Q0) and motivation (α) as separate variables within the same 
session (Bentzley, Fender et al. 2013).  Importantly, these BE measures of 
motivation and intake show individual differences that predict relapse in both 
human (Tucker, Vuchinich et al. 2002, Tucker, Vuchinich et al. 2006) and animal 






Behavioral economics of meth self-administration 
Previous models designed to assess demand curves in rodents required 
animals to stabilize responding at multiple different prices (FR values). This 
required multiple daily sessions at each price, necessitating weeks of testing to 
determine a demand curve (Oleson and Roberts 2009, Galuska, Banna et al. 
2011).  Unfortunately, this conventional method severely limits testing of acutely 
administered drugs, or brain manipulations (e.g., intracranial microinjections).  
Fortuitously, this limitation has recently been overcome with the design of the 
within-session BE procedure (Oleson, Richardson et al. 2011, Oleson and 
Roberts 2012, Bentzley, Fender et al. 2013).  However, this procedure was 
designed specifically for cocaine self-administration, based on many factors 
including the half-life of cocaine, and no comparable within-session paradigm 
had been designed for meth.   
In the cocaine within-session paradigm, it becomes increasingly more 
difficult (i.e., requires more lever presses) throughout the session to obtain the 
same amount of drug. This design is optimal for cocaine, since the half-life is so 
short (12-13 min in rats (Booze, Lehner et al. 1997)) rats will increase their effort 
to maintain their preferred blood level. However, because meth has a 
significantly longer half-life (~60 min in rats (Milesi-Halle, Hendrickson et al. 
2005)), rats learn to take more infusions of meth during low effort conditions at 
the beginning of the session and not respond under high effort conditions 
(unpublished observations, data not shown).  Thus, we designed a variation of 




Oleson, Richardson et al. 2011, Oleson and Roberts 2012, Bentzley, Fender et al. 
2013) to account for the longer half-life of meth. We validated this novel 
paradigm by verifying that calculated demand curve variables (α and Q0) were 
similar whether they were obtained in a conventional, multi-day BE paradigm or a 
within-session BE paradigm (data shown in following chapter, Fig 4-1).  
In a multi-day BE paradigm, rats self-administer drug for multiple days at 
each price (e.g., FR 1, 3, 10, 32, 100). When responding is stable at one price for 
consecutive days, the rat is moved to the next price (in ascending order). The 
stable values (total active lever presses) at each price are used to calculate a 
demand curve, thus taking an average of two weeks to determine one demand 
curve. During our within-session BE paradigm, rats are given 5 min at each price 
(i.e., FR 100, 32, 10, 3, 1) in descending order, with 20 min time-outs between 
each price. Therefore all prices are measured in one session, and structured in 
descending order to assess demand during high effort conditions before 
increased blood levels of meth confound this measurement. The demand curve 
is calculated similarly to the multi-day model, except that total lever presses from 
every 5 min price point are used, allowing a demand curve to be calculated for 
every session. Importantly, this paradigm allows for repeat testing because 
responding can be re-stabilized between tests. Figure 3-3 diagrams the 
differences in the methodology for both the multi-day paradigm (Fig 3-3A) and 





Figure 3-3 Comparison of the multi-day and within-session BE paradigms. 
A) During the multi-day BE paradigm, rats have multiple self-administration 
sessions at each price (i.e., FR value) until they reach stable responding. FR 
values increase in ascending order (FR 1, 3, 10, 32, 100) on subsequent daily 
sessions, and it takes 2 weeks on average to compute a single demand curve.   
B) During the within-session BE paradigm, rats have 5 bins (5 min each) at each 
price (FR 100, 32, 10, 3, 1) in descending order with a 20 min timeout (house 







In summary, behavioral economic analysis of self-administration provides 
a translational approach for measuring motivation and preferred consumption of 
a drug within the same session. Additionally, these measures allow for direct 
comparison between species and/or types of reinforcers and have been shown to 
correlate with addiction behaviors in humans and animals. Overall, this within-
session BE paradigm provided the ideal approach to further examine the 
possible sex differences in the effects of oxytocin on meth seeking behaviors 













Evidence suggests that oxytocin, an endogenous peptide well known for 
its role in social behaviors and childbirth, is a promising addiction 
pharmacotherapy.  We have shown that oxytocin differentially affects meth 
seeking in males vs. females on a progressive ratio (PR) test. However, in the 
PR test, meth intake progressively decreased across the course of the session. 
This change confounds the measurement of drug seeking motivation, as it is 
affected by tolerance, sensitization, locomotor activation or shifts in the preferred 
levels of drug consumption, making it unclear as to whether oxytocin is affecting 
motivation to seek meth in particular. In addition, females have higher levels of 
baseline meth consumption and because different intake levels could also 
confound PR measures (e.g., due to locomotor activation), it is difficult to 
examine sex differences in motivation for drug using this test alone. Therefore, 
we employed a within-session behavioral economic (BE) paradigm to further 




assessment of oxytocin effects on motivation (α) and preferred intake levels (Q0).   
The within-session BE paradigm was designed specifically for cocaine 
self-administration, based on many factors including the short half-life of cocaine 
(Oleson, Richardson et al. 2011, Oleson and Roberts 2012, Bentzley, Fender et 
al. 2013). As meth has a much longer half-life compared to cocaine, a variation of 
the originally published within-session BE paradigm was designed for these 
studies. The within-session BE paradigm allows measurement of drug demand at 
high effort (motivation; α), normalized based on intake at low effort (baseline 
consumption; Q0) (Bentzley, Fender et al. 2013, Bentzley, Jhou et al. 2014). The 
paradigm was modeled after BE procedures used to assess motivation for 
reward in humans (MacKillop and Murphy 2007, Mackillop, Murphy et al. 2009, 
Murphy, MacKillop et al. 2009, MacKillop, Miranda et al. 2010, MacKillop, 
O'Hagen et al. 2010). Importantly, the same BE variables (α, Q0) assessed 
across humans and animals have been shown to predict later relapse-like 
behavior (MacKillop and Murphy 2007, Galuska, Banna et al. 2011, Bentzley, 
Jhou et al. 2014).  Therefore, the translational potential of preclinical BE studies 
is particularly strong.  
In Experiment 1, we first validated the within-session BE paradigm 
designed for meth, and examined if individual variability on meth demand (α) or 
preferred levels of intake (Q0), predicts relapse behaviors. Additionally, we 
assessed the effects of oxytocin on meth demand and on cue-induced 
reinstatement in order to identify if either motivation (α) or baseline consumption 




(relapse behavior). If so, oxytocin could be screened for its efficacy in modulating 
BE variables in human drug addicts, and thereby inform clinical strategies to 
reduce the risk of subsequent relapse to drug taking.  
In Experiment 2, we examined where oxytocin may act in the brain to 
decrease meth seeking behaviors. Several studies have shown that oxytocin 
decreases reward behaviors whether administered systemically (Carson, Cornish 
et al. 2010, Carson, Hunt et al. 2010) or microinfused directly into the brain (Qi, 
Yang et al. 2008, Qi, Yang et al. 2009, Baracz, Rourke et al. 2012, Baracz, 
Everett et al. 2014), indicating that systemic oxytocin is primarily acting in the 
brain to produces its effects. However, to our knowledge, this has never been 
directly tested during a drug seeking paradigm. Therefore, we examined whether 
systemically administered oxytocin effects could be blocked by 
intracerebroventricular infusion of an oxytocin receptor antagonist (OXA).  
We then examined if nucleus accumbens (NAc) is a primary brain region 
where oxytocin acts to reduce meth seeking in our paradigm, based on 
numerous studies that show a crucial role of NAc in mediating oxytocin’s effects 
on reward-related behaviors (Liu and Wang 2003, Ross, Freeman et al. 2009, 
Keebaugh and Young 2011, Burkett and Young 2012, Dolen, Darvishzadeh et al. 
2013). Previous studies assessing oxytocin’s effects on meth-induced behaviors 
in the NAc have shown that systemically-administered oxytocin decreased meth-
induced Fos activation in NAc core (Carson, Hunt et al. 2010), and oxytocin 
microinfused into NAc core blocked meth-induced conditioned placed preference 




(Baracz, Everett et al. 2014). Although oxytocin appears to act in the brain to 
mediate rewarding effects of meth, local effects of oxytocin on meth seeking 
during BE or cue-induced reinstatement have not been assessed. Thus, we 
examined if oxytocin in NAc core is both necessary and sufficient to attenuate 





Subjects   
Male and female Sprague Dawley rats (Harlan; initial weight of 200-275 g) 
were used in all experiments. Rats were individually housed on a reversed 12:12 
light-dark cycle in a temperature and humidity controlled vivarium.  Water and rat 
chow (Harlan, Indianapolis, IN, USA) were available ad libitum throughout the 
study. All experimental protocols were approved by the Institutional Animal Care 
and Use Committee of the Medical University of South Carolina, and were in 
accordance with the eight edition of the  “Guide for the Care and Use of 
Laboratory Animals” of the Institute of Laboratory Animal Resources on Life 
Sciences, National Research Council, 2011.  
 
Surgery 
 Rats were anesthetized with IP injections of ketamine (66 mg/kg; Vedco Inc, 




USA), and Equithesin (0.5 ml/kg; sodium pentobarbital 4 mg/kg, chloral hydrate 
17 mg/kg, 21.3 mg/kg magnesium sulfate heptahydrate dissolved in 44% 
propylene glycol, 10% ethanol solution).  Ketorolac (2.0 mg/kg, IP; Sigma 
Chemical, St. Louis, MO) was given before surgery as an analgesic.  Catheters 
(constructed with Silastic tubing, Dow Corning Corporation, Midland, MI) were 
inserted 33 mm into the right jugular vein and secured with silk sutures. During 
recovery from surgery, catheters were flushed once daily for 5 days with 0.1 ml of 
Timentin (24 mg/0.1; GlaxoSmithKline, Research Triangle Park, NC) and 10 U/ml 
of heparinized saline (Elkins-Sinn, Cherry Hill, NJ). During meth self-
administration (methamphetamine hydrochloride; Sigma Chemical, St. Louis, 
MO), catheters were flushed with 0.1 ml of 10 U/ml heparinized saline before and 
after every self-administration session.  Catheter patency was periodically 
verified with methohexital sodium (10 mg/ml dissolved in 0.9% saline; Sigma 
Chemical, St. Louis, MO), a short acting barbiturate that produces a rapid loss in 
muscle tone when administered intravenously.  
 
Methamphetamine self-administration and BE procedures  
All self-administration experiments were conducted during the rats’ dark 
cycle in standard Plexiglas self-administration chambers (30 X 20 X 20 cm) that 
were enclosed in sound attenuating cubicles with a ventilation fan (Med 
Associates, St. Albans, Vermont) and linked to a computerized data collection 
program (MED PC, Med Associates).  Each chamber was equipped with two 




tone generator.  For meth self-administration, infusion tubing enclosed in steel 
spring leashes (Plastics One Inc., Roanoke, VA) was connected to the infusion 
harness and a weighted swivel apparatus (Instech, Plymouth Meeting, PA) was 
suspended above the box to allow for free movement within the chamber.    
During self-administration sessions the house light remained on 
throughout the sessions and a response on the active lever resulted in activation 
of the pump and delivery of a 2-sec meth infusion (17.5 µg/50 µl bolus for 
females and 20 µg/50 µl bolus for males) and a 5-sec presentation of a stimulus 
complex (illumination of the white stimulus light over the active lever and 
activation of tone generator; 78 dB, 4.5 kHz), followed by a 20-sec time-out.  
During the time-out period, responses on the active and inactive levers were 
recorded, but had no scheduled consequences.   
Rats acquired meth self-administration in 2-hr sessions along a fixed ratio 
(FR) 1 schedule. After meeting the acquisition criterion (5 consecutive sessions 
at >20 infusions/session and <15% variability in the last 2 days), FR values were 
increased in ascending order (FR 1, 3, 10, 32, 100) in subsequent daily sessions.   
After reaching criterion on all FR values (<15% variability in the last 2 
days), rats were switched to the within-session BE paradigm.  During this session, 
rats have 5 bins (5 min each) at each price (FR 100, 32, 10, 3, 1) in descending 
order with a 20 min timeout (house light off) between each bin (105 min total). 
Cues were presented with infusions in the same manner as during a self-
administration session.  The rats ran daily on the within-session procedure for a 




(described below) that had <25% variability of the mean of the previous 3 days.  
All testing occurred in a within subject, counterbalanced manner, with responding 
re-stabilized (to the same criterion) between each test.  
 
Demand curve analysis 
 Price is defined here as number of responses needed to obtain 1 meth 
infusion. Our primary measure of intake when effort required to obtain drug is low 
was Q0 (mg/kg/rat), and our primary measure of motivation to self-administer 
drug when effort required to obtain drug is high was α, the rate at which 
consumption decreases with increasing effort. Our primary analysis employed 
values for Q0 and α derived from the exponential demand equation in parallel 
with previous literature (Bentzley, Fender et al. 2013). Consumption data for 
each session and each rat were mathematically fit to the exponential demand 
equation by determining values for Q0 and α that minimize the sum of the 
squares of the logarithmically weighted residuals.  
 
Extinction and Reinstatement  
Following testing during the within-session BE paradigm, rats underwent a 
minimum of seven daily 2 hr extinction sessions to a criterion of <25 active lever 
presses on 2 consecutive days.  During each extinction session, responses were 
recorded on both levers, but had no programmed consequences. Upon reaching 
criteria, rats underwent cue- and/or meth-prime induced reinstatement testing. 




presentation of the light+tone stimulus complex along an FR1 schedule of 
reinforcement.  For drug-primed reinstatement tests, an injection of meth (1 
mg/kg dissolved in 0.9% physiological saline, IP) was given immediately prior to 
testing (Schwendt, Rocha et al. 2009, Reichel, Chan et al. 2012), and responses 
on either lever were recorded, but did not elicit any programmed consequences.  
Between all reinstatement tests, rats experienced a minimum of 2 extinction 
sessions, or until extinction criterion was met. 
 
Estrous cycle monitoring  
Female rats were habituated to vaginal cytology procedures during meth 
self-administration sessions.  Vaginal lumen samples were collected by gently 
flushing 30 µl of ddH20 with a sterile saline-dipped pipette tip and extracting the 
sample using a micropipette before rats were placed in the self-administration 
chambers.  Collected samples were smeared on to a glass slide, stained with 
Quik-Dip Hematology Stain (Mercedes Medical, FL), and examined for 
classification of cycle phase (estrus, proestrus, and diestrus I/II) based on 
previously published criteria (Marcondes, Bianchi et al. 2002); Feltenstein et al., 
2011) with a light microscope set at 10x magnification.   
 
Fos labeling 
Immediately following cue-induced reinstatement or extinction, rats were 
anesthetized, perfused with saline and 4% paraformaldehyde, and brains 




slices were blocked in normal donkey serum (1:500), incubated in rabbit anti-Fos 
antiserum overnight (1:10,000, Millipore) followed by incubations in a biotinylated 
donkey-anti-rabbit secondary antibody (1:500) for 2 h at room temperature, and 
an avidin-biotin complex to amplify signal.  Fos immunoreactivity was visualized 
with 3,3'-Diaminobenzidine (DAB) and 0.6% nickel ammonium sulfate to yield 
blue-black nuclei in activated cells. After mounting, sections were analyzed to 
quantify the average number of Fos+ neurons in each hemisphere from the NAc 
core. Multiple sections (3 slices/animal at 200 µm intervals) were analyzed, and 
an average for each animal was computed. Areas of interest were identified 
based on the Paxinos and Watson (2007) brain atlas and Fos+ neurons were 
quantified using standardized thresholds for size and intensity in Image J (NIH) 
by an experimenter blind to all conditions.  
 
Stereotactic surgery 
Immediately after catheter surgery, subjects were placed in a stereotactic 
frame (Kopf, Tujunga, CA, USA) and implanted with bilateral stainless steel guide 
cannulae (22 gauge, 11 mm, Plastics One, Roanoke, VA, USA) into the lateral 
ventricle at a 10° angle (-.85 posterior, ±2.0 medial–lateral, −3.0 ventral) or the 
NAc core 6° angle (+1.2 posterior, ±2.4 medial–lateral, −5.2 ventral) based on a 
rat brain atlas (Paxinos and Watson 1998). Cannulae were secured to the skull 
with jeweler’s screws and dental acrylic. Stylets were placed into the guide 






Methamphetamine HCl (Sigma) was dissolved in 0.9% sterile saline. 
Oxytocin (Cell Sciences, Canton, MA) for systemic administration was dissolved 
at 1 mg/ml in sterile saline; Cell Sciences, Canton, MA). For intracranial 
administration, oxytocin was dissolved in aCSF to 1.2 ug/ul for NAc 
microinfusions. The oxytocin antagonist d(CH2)5[Tyr(Me)2,Thr4,Orn8,des-Gly-
NH29]-vasotocin (OXA), was a gift from Dr. Maurice Manning, University of 
Toledo, OH. OXA was dissolved in aCSF to 2 ug/ul for intracerebroventricular 
(ICV) microinfusions or 1 ug/ul for NAc microinfusions.    
 
ICV microinfusions 
To test if systemically administered oxytocin acts within the brain, rats 
were stabilized on the within-session BE procedure and on subsequent sessions 
received unilateral microinfusions (28 gauge, Plastics One, Roanoke, VA, USA) 
via polyethylene tubing connected to gastight 10-µL Hamilton syringes (Hamilton, 
Reno, NV, USA) set in an infusion pump and delivered 1 µL over a 2 min period; 
injectors were left in place for an additional 2 min. All rats received 4 
microinfusions in a counterbalanced manner of OXA (2 ug/ul) or aCSF into the 
lateral ventricle immediately followed by a systemic injection of oxytocin (1 
mg/kg) or saline 30 min prior to testing. Responding during the BE paradigm was 





NAc core microinfusions 
To acclimate rats to the microinfusion procedure, injection cannulae (28 
gauge, Plastics One, Roanoke, VA, USA) extending 2 mm beyond the guide 
cannulae were bilaterally inserted (no infusions) the day prior to the first 
microinfusion test. On test days, rats received bilateral microinfusions via 
polyethylene tubing connected to gastight 10-µL Hamilton syringes (Hamilton, 
Reno, NV, USA) set in an infusion pump and delivered 0.5 µL/side over a 1 min 
period; injectors were left in place for an additional minute. To test whether 
oxytocin in the NAc core decreases meth seeking, rats were pretreated with 
microinfusions of either oxytocin (0.6 µg/side) or aCSF (in a counter balanced 
manner) 10 min prior to being tested on the within-session BE paradigm and/or 
cue-induced reinstatement. To test if oxytocin selectively acts within the NAc 
core to reduce meth seeking, rats received microinfusions of either OXA (2 
µg/µL) or aCSF into the NAc core immediately followed by a systemic injection of 
oxytocin (1 mg/kg) or saline 30 min prior to testing on the within session BE 
paradigm.  During BE testing, responding was re-stabilized (3 days <25% 
variability) between all BE tests. Rats tested on cue-induced reinstatement 
received a maximum of 2 reinstatement tests in a counterbalanced order, and 
were returned to extinction criterion between tests. All tests occurred in a 






 All statistical analyses were performed using GraphPad Prism (Version 6.01). 
Logarithmic transformations produced Gaussian distributions of α and Q0 
(Shapiro-Wilk, P > 0.05), and transformed variables were used for all analyses. 
The effects of treatment and sex were determined using a two-way analysis of 
variance (ANOVA) with post hoc analyses conducted using Bonferroni’s when 
applicable. Predictions of treatment effects were determined by multiple linear 
regression and Pearson correlation. Repeated ANOVA with Tukey’s multiple 
comparison correction was used to determine changes in α, Q0, during meth 
seeking as a consequence of microinfusion treatment. One-way ANOVA with 
Tukey’s post hoc was used for all data analysis in the Fos experiment.  
 
Results  
Experiment 1- Sex differences in the within-session BE paradigm and effects of 
oxytocin 
 
Multi-day and within-session BE paradigms show similar results 
 To validate the novel paradigm designed to assess economic demand, 
male and female rats were first trained on a traditional BE paradigm (multiple 
days at each FR value). Following training, rats were stabilized on the within-
session paradigm to test whether the traditional and novel paradigm produced 
similar results. In both paradigms, females showed greater motivation to seek 
meth (lower α) (Fig 4-1 A&C), and higher preferred consumption at null cost 
(higher Q0) than males (Fig 4-1 B&D). We further validated our within-session BE 




correlated with the same variables assessed during the within-session BE 
paradigm in both sexes (Fig 4-1 E&F). 
Due to fact that the BE paradigm necessitates many more active lever 
presses than a typical FR1 self-administration paradigm, inactive lever presses 
were very infrequent and did not differ between males and females (inactive lever 
presses-stable baseline BE males vs. females: t18=1.33, p<0.05)(data not shown). 
Therefore, inactive lever presses were not analyzed for all subsequent studies.   
 
Figure 4-1 Validation of within-session BE paradigm  
Demand variables were measured for all rats on the multi-day BE paradigm and 
then on the within-session BE paradigm. A&B) α and Q0 values for males (blue 
bars) and females (pink bars) during the multi-day BE paradigm. C&D) α and Q0 
values during the within-session BE paradigm. In both paradigms, females had 
lower α values (higher motivation) and higher Q0 values (higher intake at low FR 
values or prices) than males (*p<0.05). E&F) Correlations between α values 
measured during the multi-day and within-session BE paradigms in males (blue) 
and females (pink). In both sexes, individual α values correlated between the 
multi-day and within-session BE paradigms (Males r=0.44, p<0.05; Females 






Demand for meth (α) is related to meth intake (Q0)  
 We then assessed whether baseline economic demand for meth (α) was 
related to meth intake null cost (Q0) during the within-session BE paradigm. In 
contrast to cocaine, where these variables were unrelated in males, in both 
sexes we found a relationship between α and Q0 (male: r= -0.50, p<0.05 female: 
r= -0.44, p<0.05)(Fig 4-2A&B) measured during meth self-administration. This 
relationship also existed between the variables calculated from the multi-day BE 
paradigm (male: r= -0.51, p<0.05 female: r= -0.45, P<0.05)(data not shown). 
These results indicate that in both sexes, rats with higher intake at low effort 
conditions also show higher motivation during high effort conditions.  
 
 
Figure 4-2 Demand variables α and Q0 are related  
Baseline economic values were determined for all rats on the within-session BE 
paradigm. A) Correlation of α values with Q0 values in males (n=22 rats; r= -0.50, 







Baseline demand (α), but not consumption (Q0), during BE predicts meth 
seeking 
 We next examined whether individual differences in baseline demand (α) 
or free consumption (Q0) for meth measured during the within-session paradigm 
predicted meth seeking during abstinence. Males and females were trained on 
the within-session BE paradigm and subsequently run on daily extinction 
sessions followed by cue- and meth prime-induced reinstatement sessions. α 
predicted meth seeking (number of active lever presses) on the first day of 
extinction (males: r=-0.49, p<0.05; females: r=-0.58, p<0.01) (Fig 4-3 A&B), cue-
induced reinstatement (males: r=-0.43, p=0.05; females: r=-0.47, p<0.05) (Fig 4-
3 C&D), and meth-primed reinstatement (males: r=-0.32, p>0.05; females: r=-
0.37, p>0.05) (Fig 4-3 E&F). Males and females did not differ in any of these 
effects. As lower α values indicate greater motivation for meth, these negative 
correlations show that rats with the higher motivation (measured during BE) 
exhibited greater meth seeking during abstinence and reinstatement of meth 
seeking.  
 In contrast, there was no relationship in either sex between baseline 
consumption (Q0) and meth seeking on the first day of extinction (males: r= 0.07, 
p>0.05; females: r= 0.43, p>0.05) (Fig 4-4 A&B), cue-induced reinstatement 
(males: r= 0.20, p>0.05; females: r= 0.19, p>0.05) (Fig 4-4 C&D), or meth-primed 
reinstatement (males: r= 0.33, p>0.05; females: r= 0.23, p>0.05) (Fig 4-4 E&F). 






Figure 4-3 Economic demand predicts meth seeking behaviors.  
A&B) In both males (blue) and females (pink) α measured during the within-
session BE paradigm predicts meth seeking on extinction day one (males: r= -
0.49, p<0.05; females: r= -0.51, p<0.05). C&D) Following extinction, α predicted 
cue-induced reinstatement of meth seeking in both sexes (males: r= -0.56, 
p<0.05; females: r= -0.44, p<0.05) E&F) α did not predict meth-primed 
reinstatement in either sex (males: r= -0.35, p>0.05; females: r= -0.32, p>0.05). 







Figure 4-4 Q0 does not predict meth seeking behaviors.  
A&B) In both males (blue) and females (pink) there is no relationship between Q0 
measured during the within-session BE paradigm and meth seeking during 
extinction day one (males: r= 0.07, p>0.05; females: r= 0.43, p>0.05), C&D) cue-
induced reinstatement of meth seeking (males: r= 0.20, p>0.05; females: r= 0.19, 
p>0.05), (E&F) or meth-primed reinstatement (males: r= 0.33, p>0.05; females: 









Oxytocin decreases motivation to seek meth similarly in males and females 
 We evaluated potential sex differences in the effects of systemic oxytocin 
on demand for meth and reinstatement of meth seeking using the within-session 
BE procedure. Rats were stabilized on the within-session paradigm to determine 
baseline economic demand. On subsequent sessions, rats were pretreated with 
oxytocin (1 mg/kg i.p.) or saline (counterbalanced) 30 min prior to the BE session. 
Oxytocin increased α (decreased motivation to seek meth) in both sexes (Two-
way ANOVA, treatment main effect F(1,38) = 52.12, p<0.0001) (Fig 4-5A), but had 
no effect on Q0 (preferred intake levels) (Two-way ANOVA, Treatment F(1,38) = 
4.03, p=0.052) (Fig 4-5B). These results demonstrate that oxytocin greatly 
reduces the motivation to seek meth, but does not affect consumption at low 
effort. Rats were then extinguished and tested on cue-induced reinstatement. 
Oxytocin decreased cue-induced reinstatement in both sexes (Two-way ANOVA, 
treatment main effect, F(1,42) = 41.05, p<0.0001) (Fig 4-5C). There were no 
effects of sex in any of the measures, indicating that oxytocin decreases meth 
seeking similarly in both sexes.  
Additionally, there is no effect of estrus cycle phase on BE variables 
during within-session stabilization (α: F(2,24)=0.24, p>0.05; Q0: F(2,24)=0.02, 
p>0.05) or cue-induced reinstatement (saline: F(2,14)=1.93, p>0.05; oxytocin: 
F(2,14)=0.68, p>0.05) (data not shown). 
To determine if this BE paradigm could predict individual differences in 




demand for meth and reinstatement behavior. Individual variability in baseline 
meth demand (α) predicted the efficacy of oxytocin to decrease meth seeking 
during reinstatement similarly in both males and females (males: r= -0.45, 
p<0.05; female: -0.50, p<0.05) (Fig 4-5 D&E). Overall, there were no sex 
differences in any of the measures, indicating that oxytocin has equal efficacy at 
reducing meth seeking in both males and females, and is most effective in 







Figure 4-5 Oxytocin decreases meth seeking similarly in both sexes.  
Male (blue) and female (pink) rats were tested with oxytocin (oxy, 1 mg/kg i.p.) or 
saline (sal) during the within-session BE paradigm and cue-induced 
reinstatement of meth seeking. A) Percent change in α from baseline. In both 
sexes (male n=22, female n=21), oxytocin robustly increased α (decreased 
motivation) B) Percent change in Q0 from baseline. Oxytocin did not affect the 
percent change of Q0 in either sex (male n=22, female n=21). C) Number of 
active lever presses during cue-induced reinstatement of meth seeking. Oxytocin 
decreased cue-induced reinstatement in both sexes (male n=21, female n=23). 
Overall, a two-way ANOVA showed no effects of sex in any of these measures, 
all * indicate a significant treatment effect; *p<0.05. D&E) Baseline demand 
predicted the efficacy of oxytocin to reduce cue-induced reinstatement (change in 
cue reinstatement from saline test) in both sexes (males n=21: r= -0.45, p<0.05; 









Expirement 2- Site selectivity of oxytocin in decreasing motivation to seek 
meth 
In the next set of experiments, we examined central mechanisms of oxytocin that 
produce a decrease meth seeking. Due to the complete lack of sex differences 
with oxytocin in the previous studies, all subsequent studies were conducted only 
in male rats.  
Oxytocin antagonist ICV blocks the effects of systemic oxytocin 
Oxytocin administered systemically has been presumed to attenuate drug 
seeking via a central mechanism; however, this has not been explicitly tested. To 
directly test this, rats were first stabilized on the within-session BE paradigm to 
assess baseline meth demand (α and Q0). On subsequent sessions, all rats 
received unilateral microinfusions of OXA (2ug/1ul) or aCSF into a lateral 
ventricle immediately followed by a systemic injection of oxytocin (1 mg/kg) or 
saline in a counterbalanced manner 30 min prior to testing.  
Overall, systemic oxytocin decreased motivation, and intra-ICV antagonist 
(OXA) infusion completely blocked this effect (repeated measures ANOVA, 
F(3,15)=20.57, p<0.0001)(Fig 4-6A). Specifically, systemic oxytocin significantly 
increased α (Tukey post hoc: aCSF/sal vs. aCSF/oxy p<0.0001). OXA 
microinfused ICV immediately prior to systemic oxytocin administration blocked 
the oxytocin-induced inhibition of motivation (increase in α) to seek meth in the 
within-session BE paradigm (Tukey: aCSF/oxy vs. OXA/oxy p<0.001). There was 
no effect when the OXA was administered ICV the absence of systemic oxytocin 




the treatments on Q0 (p>0.05) (Fig 4-6B). The actions of direct OXA blockade in 
reversing systemic oxytocin effects indicates that systemic oxytocin is acting in 
the brain to reduce meth seeking.  
 
Figure 4-6 Oxytocin antagonist in the brain blocks systemic oxytocin 
effects.  
Rats stabilized on the within-session BE paradigm were tested with either 
microinfusions of OXA or aCSF (ICV) immediately followed by administration of 
oxytocin or saline (i.p.) in a counterbalanced manner. A) α values assessed 
during the within-session BE paradigm. Systemic oxytocin (aCSF/oxy, green bar) 
increased α (decreased motivation) compared to controls (aCSF/sal, blue bar). 
ICV administration of OXA blocked this effect of systemic oxytocin (OXA/oxy, red 
bar), although did not affect behavior when administered with vehicle (OXA/sal, 
orange bar). *p<0.05 compared with aCSF/oxy B) Q0 values assessed during the 








Systemic oxytocin decreases neuronal activation in NAc core  
Oxytocin in the NAc modulates reward behaviors (Baskerville and Douglas 2010, 
Carson, Hunt et al. 2010, Baracz, Rourke et al. 2012, Baracz, Everett et al. 2014). 
Thus, we determined whether Fos positive neurons in NAc core would reflect the 
ability of systemically administered oxytocin to attenuate cue-induced 
reinstatement of meth seeking. Male rats from experiment 1 were pretreated with 
oxytocin (1 mg/kg i.p.) or saline 30 min prior to a final test of either extinction or 
cue-induced reinstatement. Compared to extinction, cue-induced reinstatement 
increased active lever presses (one-way ANOVA, F(2,16)=20.82, p,0.0001; Tukey 
post hoc: EXT vs CUE SAL p<0.0001), and oxytocin attenuated reinstatement 
behavior (Tukey: CUE SAL vs. CUE OXY, p<0.001)(Fig 4-7A).  
Rats were sacrificed immediately after the session to examine neuronal 
activation in the NAc core via Fos immunohistochemistry.  Systemic oxytocin 
decreased the number of Fos activated cells in NAc core during cue-induced 
reinstatement [one-way ANOVA, F(2, 16)=4.076, p=0.0371] as compared to saline 
controls (Tukey: CUE SAL vs. CUE OXY p<0.05)(Fig 4-7B). Thus, oxytocin may 
act to reduce meth seeking via stimulation of previously identified oxytocin 





Figure 4-7 Oxytocin decreases reinstatement-induced Fos in NAc core.  
A) Number of active lever presses during extinction (EXT, black bar) or cue-
induced reinstatement of meth seeking with pretreatment of saline (CUE SAL, 
white bar) or oxytocin (1mg/kg i.p.; CUE OXY, purple bar). Oxytocin attenuated 
cue-induced reinstatement of meth seeking (*p<0.05). B) Rats were sacrificed 
immediately after the session to examine Fos expression in the NAc core of rats 
tested on either extinction (black hashed bar), cue-induced reinstatement with 
saline (white hashed bar), or oxytocin (purple hashed bar). There were less Fos 
positive neurons in the NAc core in rats treated with oxytocin prior to cue-induced 
reinstatement than saline controls (one way ANOVA *p<0.05). C) Example of Fos 
staining in each treatment group.  
 
 
Oxytocin infused into the NAc core decreases meth seeking  
To test whether oxytocin directly in NAc core decreases meth seeking, rats 




balanced manner) 10 min prior to being tested on the within-session BE 
paradigm (Fig 4-8 A&B) and cue-induced reinstatement (Fig 4-8 C). Oxytocin 
increased α compared to aCSF (t11=2.274, p=0.04), but did not alter consumption 
at low effort Q0 (t11=0.4679, p=0.07). Oxytocin decreased cue-induced 
reinstatement of meth seeking (t10=2.940, p=0.015). Overall, intra-NAc core 
oxytocin decreases meth seeking similar to systemic oxytocin.   
 
Figure 4-8 Microinfusions of oxytocin into NAc core decreases meth 
seeking. 
 A) α was increased (decreased motivation) following oxytocin microinfusions as 
compared to aCSF. B) Oxytocin microinfusions had no effect on Q0   C) Oxytocin 






Figure 4-9 NAc core microinjection sites plotted on atlas sections.  
NAc core microinjection sites plotted on atlas sections for rats in figures 4-8 and 
4-10. Schematic coronal sections were taken from Paxinos and Watson (2007), 








Systemic oxytocin effects dependent on NAc core   
Finally, to further determine whether systemic oxytocin acts within the NAc 
core to reduce meth seeking, rats were first stabilized on the within-session BE 
paradigm.  On subsequent sessions, all rats received bilateral microinfusions of 
OXA (2ug/ul) or aCSF into the NAc core immediately followed by a systemic 
injection of oxytocin (1 mg/kg) or saline 30 min prior to testing. As previously 
seen, systemic oxytocin significantly increased α (decreased motivation to seek 
meth) [Repeated measures ANOVA, F(3,21)=6.690, p=0.002; Tukey post hoc: 
aCSF/sal vs. aCSF/oxy p<0.05](Fig 4-10 A). Infusion of OXA into the NAc 
immediately prior to systemic oxytocin administration blocked the oxytocin-
induced inhibition of motivation (α) to seek meth in the within-session BE 
paradigm (Tukey: aCSF/oxy vs. OXA/oxy p<0.01). OXA had no effects when 
administered into the NAc in the absence of systemic oxytocin (Tukey: aCSF/sal 
vs. OXA/sal p>0.05). Assessing Q0 showed a statistically significant difference 
between group means [Repeated measures one-way ANOVA F(3,21) = 5.84, p = 
0.04](Fig 4-10 B); however, there were no differences between specific groups 





Figure 4-10 Oxytocin antagonist infused into NAc core blocks effect of 
systemic oxytocin Rats stabilized on the within-session BE paradigm were 
tested with either microinfusions of OXA or aCSF into the NAc core immediately 
followed by administration of oxytocin or saline (i.p.) in a counterbalanced 
manner. A) α values assessed during the within-session BE paradigm. Systemic 
oxytocin (aCSF/oxy, green bar) increased α (decreased motivation) compared to 
controls (aCSF/sal, blue bar). Intra-NAc administration of OXA blocked this effect 
of systemic oxytocin (OXA/oxy, red bar), although did not affect behavior when 
administered with vehicle (OXA/sal, orange bar). *p<0.05 compared with 
aCSF/oxy B) Q0 values assessed during the within-session BE paradigm. There 











Using a combination of meth economic demand measurement plus direct 
neural circuitry assessment, we found that oxytocin has excellent potential as a 
pharmacotherapy for meth addiction via modulation of oxytocin receptor signaling 
in the NAc core. We first successfully validated a within-session BE paradigm 
that can predict subsequent relapse-like behaviors in both males and females. 
Using this model, we determined that systemic oxytocin has similar effects of 
attenuating meth seeking in both sexes.  Importantly, oxytocin has greater effects 
in rats with the strongest addiction phenotype, regardless of sex, indicating it is 
an effective pharmacotherapy in both males and females. We then showed that 
systemic oxytocin acts primarily through a central, rather than peripheral 
mechanism to decrease meth seeking. Finally, we demonstrated that the NAc 
core was crucial for oxytocin effects on meth seeking, as it was both necessary 
and sufficient for the behavioral effects of oxytocin on meth seeking.  
 
Experiment 1 
We first validated the within-session BE paradigm for meth by showing 
similar effects in the traditional multi-day BE paradigm and the within-session 
paradigm.  In both paradigms, we confirmed previous findings that females will 
take more meth than males when increased effort is needed (i.e., PR schedule) 
(Roth and Carroll 2004, Cox, Young et al. 2013), and also take more meth on a 




relationship between α and Q0, indicating that rats with greater meth intake under 
low-effort conditions also had higher motivation during high-effort conditions. This 
finding contrasts with a recent report from our laboratory using the cocaine BE 
paradigm, where no relationship between these variables was observed 
(Bentzley, Jhou et al. 2014). This could reflect a difference in meth compared to 
cocaine or methodological differences in the two paradigms. However, it is 
unlikely to be due to the design of the meth within-session BE paradigm, as this 
relationship also exists between the variables calculated from the multi-day BE 
paradigm. This indicates that inherent differences between the two drugs 
produced the distinction, which could be due to many factors including the unique 
pharmacokinetic and pharmacodynamic profiles. 
Additionally, using the within-session BE paradigm, we replicated findings 
showing that α (measured during a multi-day BE paradigm) predicts cue-induced 
reinstatement of meth seeking in males (Galuska, Banna et al. 2011). Similar to 
results with cocaine (Bentzley, Jhou et al. 2014), α (but not Q0) predicted meth 
seeking on extinction day one and during cue-induced reinstatement. However, 
unlike cocaine, α did not predict drug-primed reinstatement of meth seeking. This 
difference could be attributed to the different pharmacokinetics of the drugs, or 
the abnormally low levels of meth-primed reinstatement in the males (as 
compared to the study in Chapter 2).  Future assessment across a range of meth 
prime doses may be useful for this paradigm.  
Previous findings indicated that oxytocin differentially affect meth seeking 




on a progressive ratio (PR) schedule of reinforcement in females, but not males, 
but attenuated reinstatement (relapse like behavior) in both sexes (Chapter 2). 
However, because meth intake during the PR test progressively decreases 
across the course of the session, the increased blood levels of meth achieved at 
the beginning of the session confounds the subsequent measurement of drug 
seeking motivation. Also, because of the longer half-life of meth as compared to 
other psychostimulants (e.g., cocaine), the PR paradigm can easily be affected 
by tolerance or other shifts in preferred levels of meth consumption, making it 
unclear as to whether oxytocin directly affects motivation to seek meth. We 
solved the problems that confound the PR paradigm by using a normalized 
measure of demand elasticity to independently measure motivation (α) and 
preferred intake levels (Q0) in the within-session BE paradigm (Bentzley, Fender 
et al. 2013). Interestingly, we saw that in both sexes oxytocin reduced motivation 
(increased α), but did not affect consumption (Q0). This indicates that oxytocin 
attenuates motivation to a similar extent in both males and females, but does not 
decrease intake under low effort conditions. This result differs from what is seen 
for cocaine in males, where oxytocin at the same dose decreased both α and Q0 
in a BE paradigm (Bentzley, Jhou et al. 2014), and both PR and FR1 schedules 
of reinforcement (Zhou, Sun et al. 2014) (note that oxytocin has not been tested 
on measures of cocaine seeking in females). Interestingly, the fact the oxytocin 
only decreases motivation but not intake at low effort appears to be a key 
difference in oxytocin attenuation of cocaine- vs. meth-seeking. Perhaps this 




cocaine (Cruickshank and Dyer 2009).  Further studies will be needed to 
determine the mechanism of oxytocin to help fully understand this difference.     
We also found that economic demand for meth predicted the efficacy of 
oxytocin to reduce subsequent cue-induced reinstatement of meth seeking. 
Specifically, in both males and females, oxytocin reduced reinstatement most in 
rats with the strongest addiction phenotype (highest initial motivation to seek 
meth). Similarly economic demand assessed in alcohol dependent individuals 
also predicted treatment outcomes (MacKillop and Murphy 2007). As economic 
demand (α) appears to have predictive validity for addiction-like behavior in rats 
(Bentzley, Jhou et al. 2014), studies should be directed at assessing 
pharmacotherapies to see if this predictive relationship occurs in human 
psychostimulant addicts.  
Overall, this model of meth seeking accurately detects sex differences in 
meth self-administration, and allows for direct comparison of pharmacotheraputic 
efficacy in both sexes. In addition, this model demonstrates that oxytocin 
attenuates meth seeking behaviors similarly in both sexes, indicating its potential 
as an effective pharmacotherapy for meth addiction in both males and females.  
 
Experiment 2 
Previous studies have examined the effects of systemic oxytocin on 
addiction-like behaviors (Carson, Cornish et al. 2010, Carson, Hunt et al. 2010, 
Cox, Young et al. 2013, Zhou, Sun et al. 2014) with the general assumption that 




produce its behavioral effects. We directly confirmed these assumptions, finding 
that an ICV infusion of an oxytocin receptor antagonist (OXA) completely blocked 
the effect of systemic oxytocin on meth seeking. Similarly, an oxytocin antagonist 
ICV has been shown to reverse the effect of systemic oxytocin on sniffing 
behavior induced by an acute injection of cocaine (Sarnyai, Babarczy et al. 1991). 
Additionally, systemically administered oxytocin activates oxytocin neurons in the 
paraventricular nucleus (PVN) (Carson, Hunt et al. 2010), presumably causing 
oxytocin release throughout the brain, including regions that modulate addiction 
behaviors.  This evidence suggests that systemic oxytocin is producing its effects 
via a central mechanism, however it is unclear specifically where systemic 
oxytocin acts to activate the central oxytocin neurons. Studies show that less 
than 1% of peripherally administered oxytocin crosses the blood brain barrier, 
presumably not enough to cause a central effect (Landgraf, Ermisch et al. 1979, 
Mens, Laczi et al. 1983, Ermisch, Barth et al. 1985). Moreover, the half-life of the 
oxytocin peptide in the periphery is only 2-10 minutes (Mens, Laczi et al. 1983), 
necessitating a secondary mechanism that would produce the long-lasting 
behavioral effects (at least 2½ h) we observed in our self-administration and 
reinstatement studies. To our knowledge, no clear secondary mechanism has 
been previously demonstrated to explain how systemic oxytocin acts centrally.  
It has been hypothesized that systemic oxytocin may stimulate the release 
of central oxytocin in the PVN via vagus nerve stimulation (Porges 1998), as the 
nucleus of the solitary tract (which receives primary visceral afferent inputs) has 




oxytocin could enter the brain via circumventricular organs, as these regions lack 
the blood brain barrier. Additionally, many of these areas are known to contain 
oxytocin receptors including area postrema, organum vasculosum of lamina, 
subfornical organ, and the median eminence (Yoshida, Takayanagi et al. 2009). 
Once oxytocin neurons in the PVN are activated, local dendritic release of 
oxytocin can cause a positive-feedback effect allowing for prolonged activation of 
the oxytocin system (Ludwig, Sabatier et al. 2002, Rossoni, Feng et al. 2008). 
Further studies are needed to examine the mechanism by which systemically 
administered oxytocin is acting to decrease meth seeking. 
 Several studies have examined the effects of oxytocin in NAc on reward 
and drug related behaviors (Ross, Freeman et al. 2009, Baskerville and Douglas 
2010, Carson, Hunt et al. 2010, Baracz, Rourke et al. 2012, Burkett and Young 
2012, Baracz, Everett et al. 2014). Therefore, we examined if systemic oxytocin 
acted through OT receptors in NAc to decrease meth seeking. Oxytocin robustly 
decreased Fos in NAc core in rats pretreated with oxytocin prior to cue-induced 
reinstatement. This finding expands on previous work that showed oxytocin 
caused a similar effect in rats acutely administered meth (Carson, Hunt et al. 
2010), by demonstrating this effect in an animal model of relapse.   
In previous studies, oxytocin infused into NAc core blocked conditioned 
place preference for meth (Baracz, Rourke et al. 2012) and decreased meth-
primed reinstatement (Baracz, Everett et al. 2014). Here, we furthered our 
understanding of the role of the NAc in oxytocin effects by demonstrating that 




(increased α) and cue-induced reinstatement for meth seeking. Importantly, intra-
NAc core oxytocin attenuated meth seeking behavior in a manner similar to 
systemic treatment, suggesting a common mechanism.  
As a final assessment, we observed that reductions in motivation driven 
by systemic oxytocin (increased α) depend on the NAc core, as OXA infused into 
the NAc blocked this effect. Although previous studies have suggested the NAc 
as a key region for oxytocin driven reduction in drug seeking (Carson, Hunt et al. 
2010, Baracz, Rourke et al. 2012, Baracz, Everett et al. 2014), the current study 
demonstrates that oxytocin in the NAc is both necessary and sufficient to do so.  
Although systemic oxytocin clearly mediates meth seeking through actions 
in the NAc core, specific cellular mechanisms are unknown. I will briefly discuss 
these mechanisms here with a more detailed discussion in the final chapter. 
Neural tracing studies confirm that oxytocin neurons in the PVN directly project to 
the NAc (Knobloch, Charlet et al. 2012, Dolen, Darvishzadeh et al. 2013), which 
when activated by systemic oxytocin may increase oxytocin release in the NAc. 
However, it is currently unclear whether oxytocin decreases meth seeking via a 
pre- or postsynaptic mechanism in the NAc core. A recent study showed that 
social conditioned place preference was dependent on the coordinated release of 
serotonin via oxytocin interactions with presynaptic receptors on dorsal raphe 
neurons that project to NAc core (Dolen, Darvishzadeh et al. 2013). Although due 
to the primary involvement of dopamine (rather than serotonin) release in NAc in 
mediating psychostimulant self-administration (Roberts, Koob et al. 1980), 




Studies have shown that oxytocin mediates drug and social reward 
behaviors (at least in part) via interactions with the mesocorticolimbic dopamine 
system (Qi, Yang et al. 2008, Qi, Yang et al. 2009, Baskerville and Douglas 2010, 
Yang, Qi et al. 2010, McGregor and Bowen 2012, Baracz and Cornish 2013). For 
example, systemic oxytocin blocked cocaine-induced dopamine release in the 
NAc (Kovacs, Sarnyai et al. 1990) and the interaction between dopamine and 
oxytocin in the NAc are necessary for pair bond formation in prairie voles (Liu 
and Wang 2003). In addition, a recent study showed that oxytocin and D2 
receptors form heteromers in the NAc (Romero-Fernandez, Borroto-Escuela et al. 
2013), suggesting oxytocin may increase inhibition via activation of these 
receptors. In summary, while oxytocin attenuated meth seeking through activity 
in NAc, future studies will be needed to determine whether the specific 
mechanism is pre- or postsynaptic and if D2-oxytocin heteromers are involved.  
In summary, we used a translational behavioral economic model to 
demonstrate that demand for meth predicts relapse-like behaviors and the 
efficacy of oxytocin to reduce these behaviors in both sexes. Moreover, these 
effects of systemic oxytocin were shown to be mediated through a central rather 
than a peripheral mechanism, and more specifically dependent on actions in the 
NAc core. However the specific cellular mechanisms of oxytocin remain to be 
determined. Together, these results indicate that oxytocin is a promising 
pharmacotherapy for meth addiction in both males and females, and emphasize 
the NAc core as the region of interest for further assessment of the mechanism 




CHAPTER 5: Conclusions 
 
 
Oxytocin as a potential pharmacotherapy for addiction 
 Currently there are no FDA approved treatments for psychostimulant 
addiction. Many hurdles or problems from a preclinical standpoint contribute to 
this fact. Here I will discuss two of the problems, as they relate to the work in this 
dissertation.  First, no established preclinical animal models exist that can 
accurately predict treatment efficacy of pharmacotherapies for psychostimulant 
addiction in humans. Second, it is clear that there are sex differences in use 
patterns and response to treatment in human meth addicts (Dluzen and Liu 
2008), indicating that females may respond differently than males to 
pharmacotherapies. Unfortunately, the vast majority of preclinical studies 
assessing potential pharmacotherapies for addiction have only used males.  The 
work in this dissertation attempts to address both of these problems by validating 
a behavioral economic model to assess meth addiction behaviors, and then 
utilizing the model to examine oxytocin’s potential as a pharmacotherapy in both 
males and females. 
.  In Chapter 2, we showed that oxytocin decreased responding on a PR 
schedule of reinforcement in females but not males, but attenuated reinstatement 




affect motivation to seek meth during self-administration and abstinence in males 
and females. However, because intake of meth may have confounded the 
measure of motivation in the PR paradigm, we further examined this effect of 
oxytocin during the BE paradigm (Chapter 4) and found that oxytocin decreased 
motivation to seek meth similarly in both sexes (but did not affect consumption). 
To understand why the two paradigms produced different results, we have to 
more carefully consider the differences between the two paradigms. During the 
PR test, the number of lever presses needed to obtain the next infusion 
increases throughout the session, whereas during BE the prices (FR value) 
decrease throughout the session. As a result, rats on a PR schedule receive 
multiple infusions at low effort conditions before motivation is assessed under 
high effort conditions. In contrast, during BE, motivation under high effort 
conditions is measured before rats can attain high blood levels of meth. This 
difference is especially important when examining effects of a drug with a long-
half life such as meth.  
Thus when comparing the paradigms, early responding during PR would 
be most similar to Q0 and later responding to α. Females showed approximately 
double the responding during the PR compared to males (increased motivation), 
and oxytocin only reduced this responding to the level of male controls. This 
indicates that oxytocin only decreased motivation under high effort conditions, 
but not at low effort (as females still received an average of 9 meth infusions), 
consistent with the effects observed in the BE paradigm. In males performing the 




generally low responding on PR, making it difficult to dissociate intake at low and 
high effort conditions. Alternatively, oxytocin could have different effects in males 
and females with high systemic meth levels. Specifically, under high blood levels 
of meth, oxytocin may decrease motivation to a greater extent in females 
compared to males. This would be consistent with data in Chapter 2 showing 
oxytocin decreased meth-primed reinstatement to a greater extent in females 
than males. These results illustrate the importance of separately assessing 
motivation and consumption.  
Importantly, by developing a variation of the within-session paradigm 
designed for cocaine (Oleson, Richardson et al. 2011, Oleson and Roberts 2012, 
Bentzley, Fender et al. 2013), we show that the same economic variables can be 
measured within-session for meth. In addition, the within-session BE model for 
meth accurately predicted addiction-like behaviors in both males and females. 
Specifically, α has been shown to predict addiction-like behaviors more 
accurately than Pmax (Murphy, MacKillop et al. 2009, Murphy, MacKillop et al. 
2011), which is similar to ‘breakpoint’ assessed in the PR schedule of 
reinforcement. In humans, α but not Pmax predicted addiction behaviors with 
alcohol and nicotine (Murphy, MacKillop et al. 2009, Murphy, MacKillop et al. 
2011). Thus, compared to PR, the BE model more accurately assesses 
motivation and predicts subsequent drug seeking behaviors. This measure of 
demand also predicted the efficacy of oxytocin to reduce reinstatement. In 
human studies economic demand also predicts treatment efficacy. In cigarette 




(McClure, Vandrey et al. 2013), while in alcohol dependent individuals, demand 
predicted overall treatment outcomes (MacKillop and Murphy 2007). Since the 
assessment of economic demand with the BE paradigm allows for direct 
comparison of rewards and manipulations across animal and human studies of 
addiction, this paradigm shows promise for use in preclinical studies to screen 
addiction pharmacotherapies for their efficacy of predicting treatment in human 
addicts.  
This BE paradigm demonstrated that oxytocin has similar efficacy in 
decreasing motivation to seek meth in males and females. This surprised us, as 
oxytocin has been shown to have differential effects on males and females for 
various social and sexual behaviors (Ross, Freeman et al. 2009, Baskerville and 
Douglas 2010, Keebaugh and Young 2011, Rutherford, Williams et al. 2011, 
Burkett and Young 2012). However, these differences may be specific to social 
and sexual behaviors, as males and females have explicitly distinct roles in these 
behaviors.  
In terms of reward related behaviors, a recent study showed that lower 
doses of oxytocin (e.g., 0.3 mg/kg) decreased sucrose-seeking in females, but 
not males (Zhou, Ghee et al. 2015), indicating that females may be more 
sensitive to lower doses of oxytocin. Although our data indicates otherwise for 
meth, as oxytocin did not decrease meth seeking behavior at that same dose 
(0.3 mg/kg) in females during meth-primed reinstatement (Fig 2-1). This indicates 
that oxytocin acts at similar doses in males and females to reduce meth seeking, 




Nevertheless, this does not preclude the possibility of sex differences in the 
effects of oxytocin on other drugs or in human addicts.  
Overall, the results of this dissertation indicate that oxytocin may be a 
successful pharmacotherapy for meth addiction in both males and females. 
Recent clinical studies in alcohol and marijuana dependent individuals also show 
promise for oxytocin as a treatment for addiction (McRae-Clark, Baker et al. 2013, 
Pedersen, Smedley et al. 2013); however, specific effects of sex were not 
examined. Future studies with humans will need to examine oxytocin’s potential 
as a pharmacotherapy for psychostimulant addiction in both sexes.  
 
Theories of oxytocin and addiction  
Several theories have been proposed to explain how oxytocin may 
decrease addiction behaviors. These theories propose that oxytocin modulates 
neural circuits related to stress, learning and memory, and social behaviors 
(McGregor and Bowen 2012, Sarnyai and Kovacs 2014). Stress is well 
characterized as one of the major contributors to relapse behaviors (Sinha 2001, 
Sinha 2007), and the anxiolytic effects of oxytocin (Neumann and Landgraf 2012, 
Smith and Wang 2012) may help to decrease relapse. In fact, oxytocin has 
recently been shown to decrease anxiety triggered by cue-induced reinstatement 
of cocaine seeking (Morales-Rivera, Hernandez-Burgos et al. 2014). Oxytocin 
has also been shown to modulate memory consolidation and retrieval (Kovacs 
and De Wied 1994, Boccia, Kopf et al. 1998, Boccia and Baratti 2000), which 




consolidation of extinction learning. However, the effect of oxytocin on learning 
and memory has not been studied in relation to addiction behaviors, thus it is 
unclear if any of these effects in basic memory performance would affect drug 
related memories.  
Finally, oxytocin facilitates social behavior, and it has been suggested that 
increased social interaction in human drug addicts may contribute to reductions 
in addiction behaviors (McGregor and Bowen 2012). A recent study showed that 
oxytocin mediates social reward through specific mechanisms in the NAc core 
(Dolen, Darvishzadeh et al. 2013). Similarly, in Chapter 4 we showed that the 
reduction of meth seeking by systemic oxytocin depends upon the NAc core. 
Thus, as significant overlap exists for the mechanisms that modulate 
social/sexual reward and addiction behaviors (Burkett and Young 2012), oxytocin 
may attenuate of drug seeking through a similar mechanism.  
 
Potential cellular mechanisms of oxytocin in NAc core 
Systemic oxytocin activates oxytocin neurons in the PVN (Carson, Hunt et 
al. 2010) and a subset of those oxytocin neurons project to the NAc core 
(Knobloch, Charlet et al. 2012, Dolen, Darvishzadeh et al. 2013). Thus, together 
with our data indicating NAc core dependent effects of systemic oxytocin, it 
appears that systemic oxytocin activates PVN oxytonergic neurons to increase 
release of oxytocin into NAc core. However, within the NAc core it is unknown 
whether oxytocin is acting via a post- or presynaptic mechanism to attenuate 




core and found that postsynaptic oxytocin receptors are only found on 
parvalbumin-positive (Parv+) interneurons and glia cells (GFAP+), and not on 
MSNs, cholinergic, or nitric oxide interneurons (Dolen, Darvishzadeh et al. 2013). 
First, these findings indicate that oxytocin may act on the Parv+ 
interneurons, and as oxytocin receptors are Gq coupled, this activation would 
inhibit GABAergic medium spiny neurons (MSNs). Selective inhibition of neurons 
in the NAc core (which is composed of >90% MSNs) can decrease cocaine 
seeking (Stefanik, Moussawi et al. 2013).  Additionally, Parv+ interneurons in 
NAc core have been shown to specifically synapse onto MSNs that project to the 
ventral tegmental area (VTA) (Bennett and Bolam 1994, Meredith 1999). The 
activation of this specific circuit may contribute to the reduction in cocaine-
induced dopamine release observed in the NAc after systemic oxytocin (Kovacs, 
Sarnyai et al. 1990), and subsequently the reduction in addiction behaviors. 
Oxytocin may also act on the astrocytes (GFAP+ glia cells) in the NAc 
core. These astrocytes contribute extensively to glutamate regulation, which is 
known to be disrupted after drug self-administration and during reinstatment 
(Kalivas 2009). Specifically, decreased extrasynaptic glutamatergic tone 
contributes to increased drug-seeking in a varety of ways. For example, 
astrocytes normally release extrasynaptic glutamate which activates mGluR2/3 
receptors located presynaptically on cortical glutamatergic axons, inhibiting 
synaptic release of glutamate (Moussawi and Kalivas 2010). However, 
extrasynaptic glutamate is disrupted in addiction, causing over-activation of the 




(Stefanik, Moussawi et al. 2013). Thus, oxytocin may act by activating astrocytes 
to increase extracellular glutamate release and restore glutamatergic tone. A 
recent study showed a similar mechanism, whereby specific activation of 
astrocytes (via a Gq coupled DREADDs) in the NAc core decreased cue-induced 
reinstatement of cocaine seeking, and this was shown to act via a mGlur2/3 
dependent mechanism (Scofield, Boger et al. 2015).  Thus, as oxytocin receptors 
are also Gq coupled and on astrocytes in NAc core, it is tempting to speculate 
that oxytocin may reduce relapse via this gilal mechanism. 
 Additionally, oxytocin acts on presynaptic receptors located on NAc core 
afferents. Since inhibition of the NAc core decreases drug seeking (Stefanik, 
Moussawi et al. 2013), it is plausible that oxytocin preferentially facilitates 
presynaptic GABAergic afferents, thereby inhibiting MSNs.  Dolen et al (2013) 
examined oxytocin receptor localization on presynaptic terminals of regions that 
project to the NAc core. These regions included PVN, anterior olfactory nucleus, 
paraventricular thalamus, basolateral amygdala, cortex of the amygdala, ventral 
hippocampal CA1 region, dorsal raphe nucleus, caudal VTA, central amygdala, 
and ventral subiculum (Dolen, Darvishzadeh et al. 2013). However, most of these 
regions are known to send predominately glutamatergic projections to NAc. 
However, some oxytocin receptor expressing inputs are predominately 
GABAergic, including central amygdala and caudal VTA. VTA projections to NAc 
are primarily dopaminergic, but a GABAergic projection to NAc core also exists 
(Van Bockstaele and Pickel 1995, van Zessen, Phillips et al. 2012). As the 




Chatelain-Badie et al. 2008), it’s possible that oxytocin receptors in NAc could 
primarily be found on presynaptic GABAergic projections from VTA. Thus, 
oxytocin could attenuate drug seeking behaviors by increasing GABA release 
from either the central amygdala or VTA to inhibit MSNs.   
Finally, a recent study showed the existence of a dopamine D2-oxytocin 
heteromer in NAc (Romero-Fernandez, Borroto-Escuela et al. 2013). These 
receptors were shown to have facilitatory allosteric interactions, meaning that 
oxytocin increased D2 binding and Gi/o coupling. This suggests that oxytocin 
could potentially inhibit glutamate release in NAc core via activation of 
presynaptic D2 receptors. However, the distribution and specific cellular 
localization of these heteromers has not been determined, making it difficult to 
draw conclusions about their contributions to oxytocin effects in meth seeking. 
However, interactions between oxytocin and dopamine are known to be required 
for many reward related behaviors (Liu and Wang 2003, Baskerville, Allard et al. 
2009, Baskerville and Douglas 2010, Burkett and Young 2012, Baracz and 
Cornish 2013), indicating that this mechanism could be plausible.  
Although a clear synaptic mechanism remains to be determined, it is 
evident that oxytocin acts within the NAc to reduce meth seeking. Oxytocin may 
attenuate drug seeking through direct interactions with the dopamine, glutamate 
or GABAergic neurotransmitter systems in the NAc core. Future studies should 
focus on examining whether oxytocin is attenuating meth seeking via a pre- or 
postsynaptic mechanism in the NAc core and if these effects extend to other 




In summary, drug addiction is associated with long-lasting neurobiological 
changes that increase relapse vulnerability.  Thus, we utilized a behavioral 
economic model to specifically examine the relationship between motivation to 
seek a meth and relapse vulnerability. Additionally, we used this model to assess 
the efficacy of oxytocin as a pharmacotherapy for addiction with the hope of 
increasing the translational potential of this data set. Specifically, oxytocin 
appears to be a promising pharmacotherapy for meth addiction because it 
decreases motivation to seek meth and attenuates relapse-like behavior in rats 
with the strongest addiction phenotype. Although few sex differences were 
observed in the effects of oxytocin, this dissertation emphasizes the importance 
of focusing on sex and individual differences for the development of efficacious 
pharmacotherapies for addiction in all populations of humans. Cumulative results 
from this dissertation indicate that oxytocin would be a promising treatment for 
meth addiction in humans, and highlight the NAc core as the region of interest for 
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